Document:

Exhibit 10.2

 

MoneyLion Inc.

 

AMENDED AND RESTATED OMNIBUS INCENTIVE PLAN

 

Amended and restated as of June 15, 2022

 

Section 1. Purpose.
The purpose of the MoneyLion Inc. Amended and Restated Omnibus Incentive Plan (as amended from time to time, the “Plan”)
is to promote the long-term success of MoneyLion Inc., a Delaware corporation (the “Company”) by motivating employees
and other individuals to perform at the highest level and contributing significantly to the success of the Company, thereby furthering
the best interests of the Company and its shareholders. The Plan shall serve as the primary plan under which equity-based incentives
are awarded on a worldwide basis to Participants.

 

Section 2. Definitions.
As used in the Plan, the following terms shall have the meanings set forth below:

 

(a) “Affiliate”
means any entity that, directly or indirectly through one or more intermediaries controls, is controlled by or is under common control
with, the Company.

 

(b) “Award”
means any Option, SAR, Restricted Stock, RSU, Performance Award, Other Cash-Based Award or Other Stock-Based Award granted under
the Plan.

 

(c) “Award Agreement”
means any agreement, contract or other instrument or document (including in electronic form) evidencing any Award granted under the Plan,
which may, but need not, be executed or acknowledged by a Participant.

 

(d) “Beneficial Owner”
has the meaning ascribed to such term in Rule 13d-3 under the Exchange Act.

 

(e) “Beneficiary”
means a Person entitled to receive payments or other benefits or exercise rights that are available under the Plan in the event of a Participant’s
death. If no such Person can be named or is named by a Participant, or if no Beneficiary designated by a Participant is eligible to receive
payments or other benefits or exercise rights that are available under the Plan at a Participant’s death, such Participant’s
Beneficiary shall be such Participant’s estate.

 

(f) “Board”
means the Board of Directors of the Company.

 

(g) “Cause”
is as defined in Participant’s Service Agreement, if any, or Award Agreement or, if not so defined, means: (i) any theft,
fraud, embezzlement, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, falsification of any documents or records
of the Company or any of its Affiliates, felony or similar act by Participant (whether or not related to Participant’s relationship
with the Company); (ii) an act of moral turpitude by Participant, or any act that causes significant injury to, or is otherwise
adversely affecting, the reputation, business, assets, operations or business relationship of the Company (or a Subsidiary or Affiliate,
when applicable); (iii) any breach by Participant of any material agreement with or of any material duty of Participant to
the Company or any Subsidiary or Affiliate thereof (including breach of confidentiality, non-disclosure, non-use non-competition or
non-solicitation covenants towards the Company or any of its Affiliates) or failure to abide by code of conduct or other policies
(including, without limitation, policies relating to confidentiality and reasonable workplace conduct); or (iv) any act which
constitutes a breach of a Participant’s fiduciary duty towards the Company or an Affiliate or Subsidiary, including disclosure of
confidential or proprietary information thereof or acceptance or solicitation to receive unauthorized or undisclosed benefits, irrespective
of their nature, or funds, or promises to receive either, from individuals, consultants or corporate entities that the Company or a Subsidiary
does business with; (v) Participant’s unauthorized use, misappropriation, destruction, or diversion of any tangible
or intangible asset or corporate opportunity of the Company or any of its Affiliates (including, without limitation, the improper use
or disclosure of confidential or proprietary information); or (vi) any circumstances that constitute grounds for termination
for cause under Participant’s Service Agreement with the Company or Affiliate, to the extent applicable. For the avoidance of doubt,
the determination as to whether a termination is for Cause for purposes of this Plan, shall be made in good faith by the Committee and
shall be final and binding on Participant.

 

      

     

    

 

(h) “Change in Control”
means the occurrence of any one or more of the following events:

 

(i) any Person, other
than (A) any employee plan established by the Company or any Subsidiary, (B) the Company or any of its Affiliates,
(C) an underwriter temporarily holding securities pursuant to an offering of such securities, or (D) an entity
owned, directly or indirectly, by shareholders of the Company in substantially the same proportions as their ownership of the Company,
is (or becomes, during any 12-month period) the Beneficial Owner, directly or indirectly, of securities of the Company (not including
in the securities beneficially owned by such Person any securities acquired directly from the Company or its Affiliates other than in
connection with the acquisition by the Company or its Affiliates of a business) representing 50% or more of the total voting power of
the stock of the Company; provided that the provisions of this subsection (i) are not intended to apply to or include
as a Change in Control any transaction that is specifically excepted from the definition of Change in Control under subsection (iii) below;

 

(ii) a change
in the composition of the Board such that, during any 12-month period, the individuals who, as of the beginning of such period, constitute
the Board (the “Existing Board”) cease for any reason to constitute at least 50% of the Board; provided, however,
that any individual becoming a member of the Board subsequent to the beginning of such period whose election, or nomination for election
by the Company’s shareholders, was approved by a vote of at least a majority of the Directors immediately prior to the date of such
appointment or election shall be considered as though such individual were a member of the Existing Board; provided further,
that, notwithstanding the foregoing, no individual whose initial assumption of office occurs as a result of either an actual or threatened
election contest (as such terms are used in Rule 14a-11 or Regulation 14A promulgated under the Exchange Act or successor
statutes or rules containing analogous concepts) or other actual or threatened solicitation of proxies or consents by or on behalf of
an individual, corporation, partnership, group, associate or other entity or Person other than the Board, shall in any event be considered
to be a member of the Existing Board;

 

(iii) the consummation
of a merger, amalgamation or consolidation of the Company with any other corporation or other entity, or the issuance of voting securities
in connection with such a transaction pursuant to applicable stock exchange requirements; provided that immediately following
such transaction the voting securities of the Company outstanding immediately prior thereto do not continue to represent (either by remaining
outstanding or by being converted into voting securities of the surviving entity of such transaction or parent entity thereof) 50% or
more of the total voting power of the Company’s stock (or, if the Company is not the surviving entity of such merger or consolidation,
50% or more of the total voting power and total fair market value of the stock of such surviving entity or parent entity thereof); and provided, further,
that such a transaction effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes
the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such
Person any securities acquired directly from the Company or its Affiliates other than in connection with the acquisition by the Company
or its Affiliates of a business) representing 50% or more of either the then-outstanding Shares or the combined voting power and
total fair market value of the Company’s then-outstanding voting securities shall not be considered a Change in Control; or

 

(iv) the sale
or disposition by the Company of all or substantially all of the Company’s assets in which any Person acquires (or has acquired
during the 12-month period ending on the date of the most recent acquisition by such Person) assets from the Company that have a
total gross fair market value equal to more than 50% of the total gross fair market value of all of the assets of the Company immediately
prior to such acquisition or acquisitions.

 

    2

     

    

 

Notwithstanding the foregoing, (A) no
Change in Control shall be deemed to have occurred if there is consummated any transaction or series of integrated transactions immediately
following which the record holders of the Shares immediately prior to such transaction or series of transactions continue to have substantially
the same proportionate ownership in an entity which owns substantially all of the assets of the Company immediately prior to such transaction
or series of transactions and (B) no Change in Control shall be deemed to have occurred upon the acquisition of additional
control of the Company by any Person that is considered to effectively control the Company. In no event will a Change in Control be deemed
to have occurred if any Participant is part of a “group” within the meaning of Section 13(d)(3) of the Exchange
Act that effects a Change in Control. Notwithstanding the foregoing or any provision of any Award Agreement to the contrary, for
any Award that provides for accelerated distribution on a Change in Control of amounts that constitute “deferred compensation”
(as defined in Section 409A of the Code), if the event that constitutes such Change in Control does not also constitute a change
in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company’s assets (in either
case, as defined in Section 409A of the Code), such amount shall not be distributed on such Change in Control but instead shall vest
as of such Change in Control and shall be distributed on the scheduled payment date specified in the applicable Award Agreement, except
to the extent that earlier distribution would not result in the Participant who holds such Award incurring interest or additional tax
under Section 409A of the Code.

 

(i) “Code”
means the Internal Revenue Code of 1986, as amended from time to time, and the rules, regulations and guidance thereunder. Any reference
to a provision in the Code shall include any successor provision thereto.

 

(j) “Committee”
means the compensation committee of the Board unless another committee is designated by the Board If there is no compensation committee
of the Board and the Board does not designate another committee, references herein to the “Committee” shall refer to the Board.

 

(k) “Consultant”
means any individual, including an advisor, who is providing bona fide services to the Company or any Subsidiary or who
has accepted an offer of service or consultancy from the Company or any Subsidiary. For purposes of the Plan, in the case of a Consultant,
references to employment shall be deemed to refer to such Consultant’s service in such capacity, but in no event shall the Plan
or any action taken hereunder be construed to create an employer-employee relationship between any such Consultant and the Company
or of any of its Affiliates.

 

(l) “Director”
means any member of the Board.

 

(m) “Effective Date”
means the date on which the Plan is adopted by the Board and approved by the shareholders of the Company.

 

(n) “Employee”
means any individual, including any officer, employed by the Company or any Subsidiary or any prospective employee or officer who has
accepted an offer of employment from the Company or any Subsidiary, with the status of employment determined based upon such factors as
are deemed appropriate by the Committee in its discretion, subject to any requirements of the Code or applicable laws; provided that
any such person may not receive any payment or exercise any right relating to an Award until such person has commenced employment or service
with the Company or its Subsidiaries. An employee on an approved leave of absence (including maternity leave) shall be considered as still
in the employment of the Company or its Subsidiaries for purposes of eligibility for participation in the Plan.

 

(o) “Exchange Act”
means the Securities Exchange Act of 1934, as amended from time to time, and the rules, regulations and guidance thereunder. Any
reference to a provision in the Exchange Act shall include any successor provision thereto.

 

(p) “Fair Market Value”
means (i) with respect to Shares, the closing price of a Share on the trading day immediately preceding the date of determination
(or, if there is no reported sale on such date, on the last preceding date on which any reported sale occurred), on the principal stock
market or exchange on which the Shares are quoted or traded, or if Shares are not so quoted or traded, the fair market value of a Share
as determined by the Committee, and (ii) with respect to any property other than Shares, the fair market value of such property
determined by such methods or procedures as shall be established from time to time by the Committee.

 

(q) “Incentive Stock
Option” means an option representing the right to purchase Shares from the Company, granted pursuant to Section 6, that
meets the requirements of Section 422 of the Code.

 

(r) “Intrinsic Value”
with respect to an Option or SAR Award means (i) the excess, if any, of the price or implied price per Share in a Change in
Control or other event over (ii) the exercise or hurdle price of such Award multiplied by (iii) the
number of Shares covered by such Award.

 

    3

     

    

 

(s) “Non-Employee Director”
means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation,
either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as
a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated
pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any other transaction for
which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which
disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee director”
for purposes of Rule 16b-3.

 

(t) “Non-Qualified Stock
Option” means an option representing the right to purchase Shares from the Company, granted pursuant to Section 6, that
is not an Incentive Stock Option.

 

(u) “Option”
means an Incentive Stock Option or a Non-Qualified Stock Option.

 

(v) “Other Cash-Based Award”
means an Award granted pursuant to Section 11, including cash awarded as a bonus or upon the attainment of specified performance
criteria or otherwise as permitted under the Plan.

 

(w) “Other Stock-Based Award”
means an Award granted pursuant to Section 11 that may be denominated or payable in, valued in whole or in part by reference to,
or otherwise based on, or related to, Shares or factors that may influence the value of Shares, including convertible or exchangeable
debt securities, other rights convertible or exchangeable into Shares, purchase rights for Shares, dividend rights or dividend equivalent
rights or Awards with value and payment contingent upon performance of the Company or business units thereof or any other factors designated
by the Committee.

 

(x) “Participant”
means the recipient of an Award granted under the Plan.

 

(y) “Performance Award”
means an Award granted pursuant to Section 10.

 

(z) “Performance Period”
means the period established by the Committee with respect to any Performance Award during which the performance goals specified by the
Committee with respect to such Award are to be measured.

 

(aa) “Person”
has the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d)
thereof, including a “group” as defined in Section 13(d) thereof.

 

(bb) “Prior Award”
means an award granted prior to the Effective Date under either of the Prior Plans.

 

(cc) “Prior Plans”
mean the MoneyLion Inc. 2014 Equity Incentive Plan and the MoneyLion Inc. Omnibus Incentive Plan.

 

(dd) “Restricted Stock”
means any Share subject to certain restrictions and forfeiture conditions, granted pursuant to Section 8.

 

(ee) “Rule 16b-3”
means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to
time.

 

(ff) “RSU”
means a contractual right granted pursuant to Section 9 that is denominated in Shares. Each RSU represents a right to receive the
value of one Share (or a percentage of such value) in cash, Shares or a combination thereof. Awards of RSUs may include the right to receive
dividend equivalents.

 

(gg) “SAR”
means a right granted pursuant to Section 7 to receive upon exercise by the Participant or settlement, in cash, Shares or a combination
thereof, the excess of (i) the Fair Market Value of one Share on the date of exercise or settlement over (ii) the
exercise or hurdle price of the right on the date of grant.

 

(hh) “Service Agreement”
means any employment, severance, consulting or similar agreement between the Company or any of its Affiliates and a Participant.

 

(ii) “Share”
means a share of the Company’s Class A common stock, $0.0001 par value.

 

    4

     

    

 

(jj) “Subsidiary”
means an entity of which the Company directly or indirectly holds all or a majority of the value of the outstanding equity interests of
such entity or a majority of the voting power with respect to the voting securities of such entity. Whether employment by or service with
a Subsidiary is included within the scope of the Plan shall be determined by the Committee.

 

(kk) “Substitute Award”
means an Award granted in assumption of, or in substitution for, an outstanding award previously granted by a company or other business
acquired by the Company or with which the Company combines.

 

(ll) “Termination
of Service” means, in the case of a Participant who is an Employee, cessation of the employment relationship such that the Participant
is no longer an employee of the Company or any Subsidiary, or, in the case of a Participant who is a Consultant or Non-Employee Director,
the date the performance of services for the Company or any Subsidiary has ended; provided, however, that in the
case of a Participant who is an Employee, the transfer of employment from the Company to a Subsidiary, from a Subsidiary to the Company,
from one Subsidiary to another Subsidiary or, unless the Committee determines otherwise, the cessation of employee status but the continuation
of the performance of services for the Company or a Subsidiary as a Director or Consultant shall not be deemed a cessation of service
that would constitute a Termination of Service; provided, further, that a Termination of Service shall be deemed
to occur for a Participant employed by, or performing services for, a Subsidiary when such Subsidiary ceases to be a Subsidiary unless
such Participant’s employment or service continues with the Company or another Subsidiary. Notwithstanding the foregoing, with respect
to any Award subject to Section 409A of the Code (and not exempt therefrom), a Termination of Service occurs when a Participant experiences
a “separation of service” (as such term is defined under Section 409A of the Code).

 

Section 3. Eligibility.

 

(a) Any Employee, Non-Employee Director
or Consultant shall be eligible to be selected to receive an Award under the Plan, to the extent that an offer or receipt of an Award
is permitted by applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations.

 

(b) Holders of equity compensation
awards granted by a company that is acquired by the Company (or whose business is acquired by the Company) or with which the Company combines
are eligible for grants of Substitute Awards under the Plan to the extent permitted under applicable regulations of any stock exchange
on which the Company is listed.

 

Section 4. Administration.

 

(a) Administration
of the Plan. The Plan shall be administered by the Committee. All decisions of the Committee shall be final, conclusive and binding
upon all parties, including the Company, its shareholders, Participants and any Beneficiaries thereof. The Committee may issue rules and
regulations for administration of the Plan.

 

(b) Delegation of Authority.
To the extent permitted by applicable law, including under Section 157(c) of the Delaware General Corporation Law, the Committee
may delegate to one or more officers of the Company some or all of its authority under the Plan, including the authority to grant Options
and SARs or other Awards in the form of Share rights (except that such delegation shall not apply to any Award for a Person then covered
by Section 16 of the Exchange Act), and the Committee may delegate to one or more committees of the Board (which may consist
of solely one Director) some or all of its authority under the Plan, including the authority to grant all types of Awards, in accordance
with applicable law.

 

(c) Authority of Committee.
Subject to the terms of the Plan and applicable law, the Committee (or its delegate) shall have full discretion and authority to: (i) designate
Participants; (ii) determine the type or types of Awards (including Substitute Awards) to be granted to each Participant under
the Plan; (iii) determine the number of Shares to be covered by (or with respect to which payments, rights or other matters
are to be calculated in connection with) Awards; (iv) determine the terms and conditions of any Award and prescribe the form
of each Award Agreement, which need not be identical for each Participant; (v) determine whether, to what extent, under what
circumstances and by which methods Awards may be settled or exercised in cash, Shares, other Awards, other property, net settlement (including
broker-assisted cashless exercise), or any combination thereof, or canceled, forfeited or suspended; (vi) determine whether,
to what extent and under what circumstances cash, Shares, other Awards, other property and other amounts payable with respect to an Award
under the Plan shall be deferred either automatically or at the election of the holder thereof or of the Committee; (vii) amend
terms or conditions of any outstanding Awards; (viii) correct any defect, supply any omission and reconcile any inconsistency
in the Plan or any Award, in the manner and to the extent it shall deem desirable to carry the Plan into effect; (ix) interpret
and administer the Plan and any instrument or agreement relating to, or Award made under, the Plan; (x) establish, amend,
suspend or waive such rules and regulations and appoint such agents, trustees, brokers, depositories and advisors and determine such terms
of their engagement as it shall deem appropriate for the proper administration of the Plan and due compliance with applicable law, stock
market or exchange rules and regulations or accounting or tax rules and regulations; and (xi) make any other determination
and take any other action that the Committee deems necessary or desirable for the administration of the Plan and due compliance with applicable
law, stock market or exchange rules and regulations or accounting or tax rules and regulations. Notwithstanding anything to the contrary
contained herein, the Board may, in its sole discretion, at any time and from time to time, grant Awards or administer the Plan. In any
such case, the Board shall have all of the authority and responsibility granted to the Committee herein.

 

    5

     

    

 

(d) Rule 16b-3 Compliance. To
the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act that is available under
Rule 16b-3 of the Exchange Act, the Award will be granted by the Board or a Committee (or a subcommittee thereof) that
consists solely of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) of the Exchange Act and
thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee (or a subcommittee)
meeting such requirements to the extent necessary for such exemption to remain available.

 

Section 5. Shares
Available for Awards.

 

(a) Subject to adjustment as
provided in Section 5(c) and except for Substitute Awards, the maximum number of Shares available for issuance under the Plan shall
not exceed in the aggregate 14,061,702 Shares and up to 65,235,347 Shares subject to the outstanding Prior Awards as of
the Effective Date. The total number of Shares available for issuance under the Plan shall be increased on January 1 of each fiscal
year beginning on January 1, 2023 and ending on January 1, 2031 in an amount equal to the lesser of (i) 5% of the total number
of shares of all classes of the Company’s voting stock outstanding on the last day of the immediately preceding fiscal year and
(ii) such number of Shares as determined by the Committee in its discretion. Shares underlying Substitute Awards and Shares
remaining available for grant under a plan of an acquired company or of a company with which the Company combines (whether by way of amalgamation,
merger, sale and purchase of shares or other securities or otherwise), appropriately adjusted to reflect the acquisition or combination
transaction, shall not reduce the number of Shares remaining available for grant hereunder.

 

(b) If any Award or Prior Award
is forfeited, cancelled, expires, terminates or otherwise lapses or is settled in cash, in whole or in part, without the delivery of Shares,
then the Shares covered by such forfeited, expired, terminated or lapsed Award or Prior Award shall again be available for grant under
the Plan. The following shall become available for issuance under the Plan: (i) any Shares withheld in respect of taxes relating
to any Award or Prior Award and (ii) any Shares tendered or withheld to pay the exercise price of Options or Prior Awards.

 

(c) In the event that the Committee
determines that, as a result of any dividend or other distribution (other than an ordinary dividend or distribution), recapitalization,
stock split, reverse stock split, reorganization, merger, amalgamation, consolidation, separation, rights offering, split-up, spin-off,
combination, repurchase or exchange of Shares or other securities of the Company, issuance of warrants or other rights to acquire Shares
or other securities of the Company, issuance of Shares pursuant to the anti-dilution provisions of securities of the Company, or
other similar corporate transaction or event affecting the Shares, or of changes in applicable laws, regulations or accounting principles,
an adjustment is necessary in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available
under the Plan, then the Committee shall, subject to Section 19 and applicable law, adjust equitably so as to ensure no undue enrichment
or harm (including by payment of cash), any or all of:

 

(i) the number and
type of Shares (or other securities) which thereafter may be made the subject of Awards, including the aggregate limits specified in Section 5(a)
and Section 5(f);

 

(ii) the number
and type of Shares (or other securities) subject to outstanding Awards;

 

    6

     

    

 

(iii) the grant,
acquisition, exercise or hurdle price with respect to any Award or, if deemed appropriate, make provision for a cash payment to the holder
of an outstanding Award; and

 

(iv) the terms and
conditions of any outstanding Awards, including the performance criteria of any Performance Awards;

 

provided, however, that the
number of Shares subject to any Award denominated in Shares shall always be a whole number.

 

(d) Any Shares delivered pursuant
to an Award may consist, in whole or in part, of authorized and unissued Shares or Shares acquired by the Company.

 

(e) The aggregate value of
all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director with respect to any calendar
year, including Awards granted and cash fees paid by the Company to such Non-Employee Director, will not exceed (i) $750,000
in total value or (ii) in the event such Non-Employee Director is first appointed or elected to the Board, $1,000,000
in total value during the initial annual period, in each case calculating the value of any equity awards based on the grant date fair
value of such equity awards for financial reporting purposes. The limitations in this Section 5(e) shall apply commencing with the
first calendar year that begins following September 21, 2021.

 

(f) Subject to adjustment as
provided in Section 5(c)(i), the maximum number of Shares available for issuance with respect to Incentive Stock Options shall be
70,510,395. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Shares with respect to which Incentive
Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any
Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive
Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise
do not comply with such rules will be treated as Nonqualified Stock Options, notwithstanding any contrary provision of the applicable
Option Agreement(s).

 

Section 6. Options.
The Committee is authorized to grant Options to Participants with the following terms and conditions and with such additional terms and
conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall determine:

 

(a) The exercise price per
Share under an Option shall be determined by the Committee at the time of grant; provided, however, that, except
in the case of Substitute Awards, such exercise price shall not be less than the Fair Market Value of a Share on the date of grant of
such Option.

 

(b) The term of each Option
shall be fixed by the Committee but shall not exceed 10 years from the date of grant of such Option.

 

(c) The Committee shall determine
the methods by which, and the forms in which payment of the exercise price with respect thereto may be made or deemed to have been made,
including cash, Shares, other Awards, other property, net settlement (including broker-assisted cashless exercise) or any combination
thereof, having a Fair Market Value on the exercise date equal to the relevant exercise price.

 

(d) To the extent an Option
is not previously exercised as to all of the Shares subject thereto, and, if the Fair Market Value of one Share is greater than the exercise
price then in effect, then the Option shall be deemed automatically exercised immediately before its expiration.

 

(e) No grant of Options may
be accompanied by a tandem award of dividend equivalents or provide for dividends, dividend equivalents or other distributions to be paid
on such Options (except as provided under Section 5(c)).

 

    7

     

    

 

(f) The terms of any Incentive
Stock Option granted under the Plan shall comply in all respects with the provisions of Section 422 of the Code. Incentive Stock
Options may be granted only to employees of the Company or of a parent or subsidiary corporation (as defined in Section 424 of the
Code).

 

Section 7. Stock
Appreciation Rights. The Committee is authorized to grant SARs to Participants with the following terms and conditions and with such
additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall determine:

 

(a) SARs may be granted under
the Plan to Participants either alone (“freestanding”) or in addition to other Awards granted under the Plan (“tandem”)
and may, but need not, relate to a specific Option granted under Section 6.

 

(b) The exercise or hurdle
price per Share under a SAR shall be determined by the Committee; provided, however, that, except in the case
of Substitute Awards, such exercise or hurdle price shall not be less than the Fair Market Value of a Share on the date of grant of such
SAR.

 

(c) The term of each SAR shall
be fixed by the Committee but shall not exceed 10 years from the date of grant of such SAR.

 

(d) Upon the exercise of a
SAR, the Company shall pay to the Participant an amount equal to the number of Shares subject to the SAR multiplied by the excess, if
any, of the Fair Market Value of one Share on the exercise date over the exercise or hurdle price of such SAR. The Company shall pay such
excess in cash, in Shares valued at Fair Market Value, or any combination thereof, as determined by the Committee.

 

(e) To the extent a SAR is
not previously exercised as to all of the Shares subject thereto, and, if the Fair Market Value of one Share is greater than the exercise
price then in effect, then the SAR shall be deemed automatically exercised immediately before its expiration.

 

(f) No grant of SARs may be
accompanied by a tandem award of dividend equivalents or provide for dividends, dividend equivalents or other distributions to be paid
on such SARs (except as provided under Section 5(c)).

 

Section 8. Restricted
Stock. The Committee is authorized to grant Awards of Restricted Stock to Participants with the following terms and conditions
and with such additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall
determine:

 

(a) The Award Agreement shall
specify the vesting schedule.

 

(b) Awards of Restricted Stock
shall be subject to such restrictions as the Committee may impose, which restrictions may lapse separately or in combination at such time
or times, in such installments or otherwise, as the Committee may deem appropriate.

 

(c) Subject to the restrictions
set forth in the applicable Award Agreement, a Participant generally shall have the rights and privileges of a shareholder with respect
to Awards of Restricted Stock, including the right to vote such Shares of Restricted Stock and the right to receive dividends.

 

(d) The Committee may, in its
discretion, specify in the applicable Award Agreement that any or all dividends or other distributions paid on Awards of Restricted Stock
prior to vesting be paid either in cash or in additional Shares and either on a current or deferred basis and that such dividends or other
distributions may be reinvested in additional Shares, which may be subject to the same restrictions as the underlying Awards.

 

(e) Any Award of Restricted
Stock may be evidenced in such manner as the Committee may deem appropriate, including book-entry registration.

 

    8

     

    

 

(f) The Committee may provide in
an Award Agreement that an Award of Restricted Stock is conditioned upon the Participant making or refraining from making an election
with respect to the Award under Section 83(b) of the Code. If a Participant makes an election pursuant to Section 83(b) of
the Code with respect to an Award of Restricted Stock, such Participant shall be required to file promptly a copy of such election with
the Company and the applicable Internal Revenue Service office.

 

Section 9. RSUs. The
Committee is authorized to grant Awards of RSUs to Participants with the following terms and conditions and with such additional terms
and conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall determine:

 

(a) The Award Agreement shall specify
the vesting schedule and the delivery schedule (which may include deferred delivery later than the vesting date).

 

(b) Awards of RSUs shall be subject
to such restrictions as the Committee may impose, which restrictions may lapse separately or in combination at such time or times, in
such installments or otherwise, as the Committee may deem appropriate.

 

(c) An RSU shall not convey to
a Participant the rights and privileges of a shareholder with respect to the Share subject to such RSU, such as the right to vote or the
right to receive dividends, unless and until and to the extent a Share is issued to such Participant to settle such RSU.

 

(d) The Committee may, in its discretion,
specify in the applicable Award Agreement that any or all dividend equivalents or other distributions paid on Awards of RSUs prior to
vesting or settlement, as applicable, be paid either in cash or in additional Shares and either on a current or deferred basis and that
such dividend equivalents or other distributions may be reinvested in additional Shares, which may be subject to the same restrictions
as such Awards.

 

(e) Shares delivered upon the vesting
and settlement of an RSU Award may be evidenced in such manner as the Committee may deem appropriate, including book-entry registration.

 

(f) The Committee may determine
the form or forms (including cash, Shares, other Awards, other property or any combination thereof) in which payment of the amount owing
upon settlement of any RSU Award may be made.

 

Section 10. Performance
Awards. The Committee is authorized to grant Performance Awards to Participants with the following terms and conditions and with
such additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall determine:

 

(a) Performance Awards may be denominated
as a cash amount, number of Shares or units or a combination thereof and are Awards that may be earned upon achievement or satisfaction
of performance conditions specified by the Committee. In addition, the Committee may specify that any other Award shall constitute a Performance
Award by conditioning the grant to a Participant or the right of a Participant to exercise the Award or have it settled, and the timing
thereof, upon achievement or satisfaction of such performance conditions as may be specified by the Committee. The Committee may use such
business criteria and other measures of performance as it may deem appropriate in establishing any performance conditions. Subject to
the terms of the Plan, the performance goals to be achieved during any Performance Period, the length of any Performance Period, the amount
of any Performance Award granted and the amount of any payment or transfer to be made pursuant to any Performance Award shall be determined
by the Committee.

 

(b) Performance criteria may be
measured on an absolute (e.g., plan or budget) or relative basis, and may be established on a corporate-wide basis, with respect
to one or more business units, divisions, Subsidiaries or business segments, or on an individual basis. If the Committee determines that
a change in the business, operations, corporate structure or capital structure of the Company, or the manner in which the Company conducts
its business, or other events or circumstances render the performance objectives unsuitable, the Committee may modify the performance
objectives or the related minimum acceptable level of achievement, in whole or in part, as the Committee deems appropriate and equitable
such that it does not provide any undue enrichment or harm. Performance measures may vary from Performance Award to Performance Award
and from Participant to Participant, and may be established on a stand-alone basis, in tandem or in the alternative. The Committee
shall have the power to impose such other restrictions on Awards subject to this Section 10(b) as it may deem necessary or appropriate
to ensure that such Awards satisfy all requirements of any applicable law, stock market or exchange rules and regulations or accounting
or tax rules and regulations.

 

    9

     

    

 

(c) Settlement of Performance Awards
shall be in cash, Shares, other Awards, other property, net settlement, or any combination thereof, as determined in the discretion of
the Committee.

 

(d) A Performance Award shall not
convey to a Participant the rights and privileges of a shareholder with respect to the Share subject to such Performance Award, such as
the right to vote (except as relates to Restricted Stock) or the right to receive dividends, unless and until and to the extent a Share
is issued to such Participant to settle such Performance Award. The Committee, in its sole discretion, may provide that a Performance
Award shall convey the right to receive dividend equivalents on the Shares subject to such Performance Award with respect to any dividends
declared during the period that such Performance Award is outstanding, in which case, such dividend equivalent rights shall accumulate
and shall be paid in cash or Shares on the settlement date of the Performance Award, subject to the Participant’s earning of the
Shares with respect to which such dividend equivalents are paid upon achievement or satisfaction of performance conditions specified by
the Committee. Shares delivered upon the vesting and settlement of a Performance Award may be evidenced in such manner as the Committee
may deem appropriate, including book-entry registration. For the avoidance of doubt, unless otherwise determined by the Committee,
no dividend equivalent rights shall be provided with respect to any Shares subject to Performance Awards that are not earned or otherwise
do not vest or settle pursuant to their terms.

 

(e) The Committee may, in its discretion,
increase or reduce the amount of a settlement otherwise to be made in connection with a Performance Award.

 

Section 11. Other
Cash-Based Awards and Other Stock-Based Awards. The Committee is authorized, subject to limitations under applicable
law, to grant Other Cash-Based Awards (either independently or as an element of or supplement to any other Award under the Plan)
and Other Stock-Based Awards. The Committee shall determine the terms and conditions of such Awards. Shares delivered pursuant to
an Award in the nature of a purchase right granted under this Section 11 shall be purchased for such consideration, and paid for
at such times, by such methods and in such forms, including cash, Shares, other Awards, other property, net settlement, broker-assisted cashless
exercise or any combination thereof, as the Committee shall determine; provided that the purchase price therefor shall
not be less than the Fair Market Value of such Shares on the date of grant of such right.

 

Section 12. Effect
of Termination of Service or a Change in Control on Awards.

 

(a) The Committee may provide,
by rule or regulation or in any applicable Award Agreement, or may determine in any individual case, the circumstances in which,
and the extent to which, an Award may be exercised, settled, vested, paid or forfeited in the event of a Participant’s Termination
of Service prior to the end of a Performance Period or vesting, exercise or settlement of such Award.

 

(b) Subject to the last sentence
of Section 2(jj), the Committee may determine, in its discretion, whether, and the extent to which, (i) an Award will
vest during a leave of absence, (ii) a reduction in service level (for example, from full-time to part-time employment)
will cause a reduction, or other change, to an Award and (iii) a leave of absence or reduction in service will be deemed a
Termination of Service.

 

(c) In the event of a Change in
Control, the Committee may, in its sole discretion, and on such terms and conditions as it deems appropriate, take any one or more of
the following actions with respect to any outstanding Award, which need not be uniform with respect to all Participants and/or Awards:

 

(i) continuation or assumption
of such Award by the Company (if it is the surviving corporation) or by the successor or surviving entity or its parent;

 

(ii) substitution
or replacement of such Award by the successor or surviving entity or its parent with cash, securities, rights or other property to be
paid or issued, as the case may be, by the successor or surviving entity (or a parent or subsidiary thereof), with substantially the same
terms and value as such Award (including any applicable performance targets or criteria with respect thereto);

 

    10

     

    

 

(iii) acceleration
of the vesting of such Award and the lapse of any restrictions thereon and, in the case of an Option or SAR Award, acceleration of the
right to exercise such Award during a specified period (and the termination of such Option or SAR Award without payment of any consideration
therefor to the extent such Award is not timely exercised), in each case, either (A) immediately prior to or as of the date
of the Change in Control, (B) upon a Participant’s involuntary Termination of Service (including upon a termination
of the Participant’s employment by the Company (or a successor corporation or its parent) without Cause, by a Participant for “good
reason” and/or due to a Participant’s death or “disability”, as such terms may be defined in the applicable Award
Agreement and/or a Participant’s Service Agreement, as the case may be) on or within a specified period following the Change in
Control or (C) upon the failure of the successor or surviving entity (or its parent) to continue or assume such Award;

 

(iv) in the case
of a Performance Award, determination of the level of attainment of the applicable performance condition(s); and

 

(v) cancellation of such
Award in consideration of a payment, with the form, amount and timing of such payment determined by the Committee in its sole discretion,
subject to the following: (A) such payment shall be made in cash, securities, rights and/or other property; (B) the
amount of such payment shall equal the value of such Award, as determined by the Committee in its sole discretion; provided that,
in the case of an Option or SAR Award, if such value equals the Intrinsic Value of such Award, such value shall be deemed to be valid; provided
further that, if the Intrinsic Value of an Option or SAR Award is equal to or less than zero, the Committee may, in its sole
discretion, provide for the cancellation of such Award without payment of any consideration therefor (for the avoidance of doubt, in the
event of a Change in Control, the Committee may, in its sole discretion, terminate any Option or SAR Awards for which the exercise or
hurdle price is equal to or exceeds the per Share value of the consideration to be paid in the Change in Control transaction without payment
of consideration therefor); and (C) such payment shall be made promptly following such Change in Control or on a specified
date or dates following such Change in Control; provided that the timing of such payment shall comply with Section 409A
of the Code.

 

Section 13. General
Provisions Applicable to Awards.

 

(a) Awards shall be granted for
such cash or other consideration, if any, as the Committee determines; provided that in no event shall Awards be issued
for less than such minimal consideration as may be required by applicable law.

 

(b) Awards may, in the discretion
of the Committee, be granted either alone or in addition to or in tandem with any other Award or any award granted under any other plan
of the Company. Awards granted in addition to or in tandem with other Awards, or in addition to or in tandem with awards granted under
any other plan of the Company, may be granted either at the same time as or at a different time from the grant of such other Awards or
awards.

 

(c) Subject to the terms of the
Plan, payments or transfers to be made by the Company upon the grant, exercise or settlement of an Award may be made in the form of cash,
Shares, other Awards, other property, net settlement, or any combination thereof, as determined by the Committee in its discretion at
the time of grant, and may be made in a single payment or transfer, in installments or on a deferred basis, in each case in accordance
with rules and procedures established by the Committee. Such rules and procedures may include provisions for the payment or crediting
of reasonable interest on installment or deferred payments or the grant or crediting of dividend equivalents in respect of installment
or deferred payments.

 

(d) Except as may be permitted
by the Committee or as specifically provided in an Award Agreement, (i) no Award and no right under any Award shall be assignable,
alienable, saleable or transferable by a Participant other than by will or pursuant to Section 13(e) and (ii) during
a Participant’s lifetime, each Award, and each right under any Award, shall be exercisable only by such Participant or, if permissible
under applicable law, by such Participant’s guardian or legal representative. The provisions of this Section 13(d) shall not
apply to any Award that has been fully exercised or settled, as the case may be, and shall not preclude forfeiture of an Award in accordance
with the terms thereof.

 

    11

     

    

 

(e) A Participant may designate
a Beneficiary or change a previous Beneficiary designation only at such times as prescribed by the Committee, in its sole discretion,
and only by using forms and following procedures approved or accepted by the Committee for that purpose.

 

(f) All certificates, if any, for
Shares and/or other securities delivered under the Plan pursuant to any Award or the exercise or settlement thereof shall be subject to
such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan or the rules, regulations and other
requirements of the Securities and Exchange Commission, any stock market or exchange upon which such Shares or other securities are then
quoted, traded or listed, and any applicable securities laws, and the Committee may cause a legend or legends to be put on any such certificates
to make appropriate reference to such restrictions.

 

(g) The Company will not be obligated
to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i) all
Award conditions have been met or removed to the Committee’s satisfaction, (ii) as determined by the Committee, all
other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws,
stock market or exchange rules and regulations or accounting or tax rules and regulations and (iii) the Participant has executed
and delivered to the Company such representations or agreements as the Committee deems necessary or appropriate to satisfy any applicable
laws. The Company’s inability to obtain authority from any regulatory body having jurisdiction, which the Committee determines is
necessary to the lawful issuance and sale of any Shares, will relieve the Company of any liability for failing to issue or sell such Shares
as to which such requisite authority has not been obtained.

 

(h) The Committee may impose restrictions
on any Award with respect to non-competition, non-solicitation, confidentiality and other restrictive covenants, or requirements to comply
with minimum share ownership requirements, as it deems necessary or appropriate in its sole discretion, which such restrictions may be
set forth in any applicable Award Agreement or otherwise.

 

Section 14. Amendments
and Terminations.

 

(a) Amendment or Termination
of the Plan. Except to the extent prohibited by applicable law and unless otherwise expressly provided in an Award Agreement or in
the Plan, the Board may amend, alter, suspend, discontinue or terminate the Plan or any portion thereof at any time; provided, however,
that no such amendment, alteration, suspension, discontinuation or termination shall be made without (i) shareholder approval
if such approval is required by applicable law or the rules of the stock market or exchange, if any, on which the Shares are principally
quoted or traded or (ii) subject to Section 5(c) and Section 12, the consent of the affected Participant, if such
action would materially adversely affect the rights of such Participant under any outstanding Award, except (x) to the extent
any such amendment, alteration, suspension, discontinuance or termination is made to cause the Plan to comply with applicable law, stock
market or exchange rules and regulations or accounting or tax rules and regulations or (y) to impose any “clawback”
or recoupment provisions on any Awards (including any amounts or benefits arising from such Awards) in accordance with Section 18.
Notwithstanding anything to the contrary in the Plan, the Committee may amend the Plan, or create sub-plans, in such manner as may be
necessary or desirable to enable the Plan to achieve its stated purposes in any jurisdiction in a tax-efficient manner and in compliance
with local rules and regulations.

 

(b) Dissolution or Liquidation.
In the event of the dissolution or liquidation of the Company, each Award shall terminate immediately prior to the consummation of such
action, unless otherwise determined by the Committee.

 

(c) Terms of Awards.
The Committee may waive any conditions or rights under, amend any terms of, or amend, alter, suspend, discontinue or terminate any Award
theretofore granted (including by substituting another Award of the same or a different type), prospectively or retroactively, without
the consent of any relevant Participant or holder or Beneficiary of an Award; provided, however, that, subject
to Section 5(c) and Section 12, no such action shall materially adversely affect the rights of any affected Participant or holder
or Beneficiary under any Award theretofore granted under the Plan, except (x) to the extent any such action is made to cause
the Plan or Award to comply with applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations,
or (y) to impose any “clawback” or recoupment provisions on any Awards (including any amounts or benefits arising
from such Awards) in accordance with Section 18. The Committee shall be authorized to make adjustments in the terms and conditions
of, and the criteria included in, Awards in recognition of events (including the events described in Section 5(c)) affecting the
Company, or the financial statements of the Company, or of changes in applicable laws, regulations or accounting principles, whenever
the Committee determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential
benefits intended to be made available under the Plan.

 

    12

     

    

 

(d) No Repricing. Except
as provided in Section 5(c), the Committee may not, without shareholder approval, seek to effect any re-pricing of any previously
granted “underwater” Option, SAR or similar Award by: (i) amending or modifying the terms of the Option, SAR or
similar Award to lower the exercise price; (ii) cancelling the underwater Option, SAR or similar Award and granting either
(A) replacement Options, SARs or similar Awards having a lower exercise price or (B) Restricted Shares, RSUs,
Performance Awards or Other Share-Based Awards in exchange; or (iii) cancelling or repurchasing the underwater Options,
SARs or similar Awards for cash or other securities. An Option, SAR or similar Award will be deemed to be “underwater” at
any time when the Fair Market Value of the Shares covered by such Award is less than the exercise price of the Award.

 

Section 15. Miscellaneous.

 

(a) No Employee, Consultant, Non-Employee Director,
Participant, or other Person shall have any claim to be granted any Award under the Plan, and there is no obligation for uniformity of
treatment of employees, Participants or holders or Beneficiaries of Awards under the Plan. The terms and conditions of Awards need not
be the same with respect to each recipient. Any Award granted under the Plan shall be a one-time Award that does not constitute a
promise of future grants. The Company, in its sole discretion, maintains the right to make available future grants under the Plan.

 

(b) The grant of an Award shall
not be construed as giving a Participant the right to be retained in the employ of, or to continue to provide services to, the Company
or any Affiliate. Further, the Company or any applicable Affiliate may at any time dismiss a Participant, free from any liability, or
any claim under the Plan, unless otherwise expressly provided in the Plan or in any Award Agreement or in any other agreement binding
on the parties. The receipt of any Award under the Plan is not intended to confer any rights on the receiving Participant except as set
forth in the applicable Award Agreement.

 

(c) In the event a Participant’s
regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example,
and without limitation, if the Participant is an employee of the Company and the Employee has a change in status from a full-time employee
to a part-time employee (or serves as a Consultant or Director) or takes an extended leave of absence) after the date of grant of
any Award to the Participant, the Board may determine, to the extent permitted by applicable law, to (i) make a corresponding
reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after
the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting
or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any
portion of the Award that is so reduced or extended.

 

(d) As a condition to accepting
an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined
in the Committee’s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or
other regulatory requirements, in each case at the Committee’s request.

 

(e) No payment pursuant to the
Plan shall be taken into account in determining any benefits under any severance, pension, retirement, savings, profit sharing, group
insurance, welfare or other benefit plan of the Company or any Affiliate, except to the extent otherwise expressly provided in writing
in such other plan or an agreement thereunder.

 

(f) Nothing contained in the Plan
shall prevent the Company or any Affiliate from adopting or continuing in effect other or additional compensation arrangements, including
the grant of options and other stock-based awards, and such arrangements may be either generally applicable or applicable only in
specific cases.

 

(e) The Company shall be authorized
to withhold from any Award granted or any payment due or transfer made under any Award or under the Plan or from any compensation or other
amount owing to a Participant the amount (in cash, Shares, other Awards, other property, net settlement, or any combination thereof) of
applicable withholding taxes due in respect of an Award, its exercise or settlement or any payment or transfer under such Award or under
the Plan and to take such other action (including providing for elective payment of such amounts in cash or Shares by such Participant)
as may be necessary to satisfy all obligations for the payment of such taxes and, unless otherwise determined by the Committee in its
discretion, to the extent such withholding would not result in liability classification of such Award (or any portion thereof) pursuant
to FASB ASC Subtopic 718-10. As a condition to accepting an Award under the Plan, in the event that the amount of the Company’s
and/or its Affiliate’s withholding obligation in connection with such Award was greater than the amount actually withheld by the
Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure
by the Company and/or its Affiliates to withhold the proper amount.

 

    13

     

    

 

(g) If any provision of the Plan
or any Award Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction, or as to any Person or
Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or
deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee,
materially altering the intent of the Plan or the Award Agreement, such provision shall be stricken as to such jurisdiction, Person or
Award, and the remainder of the Plan and any such Award Agreement shall remain in full force and effect.

 

(h) Neither the Plan nor any Award
shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company and a Participant
or any other Person. To the extent that any Person acquires a right to receive payments from the Company pursuant to an Award, such right
shall be no greater than the right of any unsecured general creditor of the Company.

 

(i) Any reference herein or in
an Award Agreement to a “written” agreement or document will include any agreement or document delivered electronically, filed
publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared
electronic medium controlled by the Company to which the Participant has access). By accepting any Award, the Participant consents to
receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained
by the Committee’s or another third party selected by the Committee. The form of delivery of any Shares (e.g., a stock certificate
or electronic entry evidencing such shares) shall be determined by the Company.

 

(j) No fractional Shares shall
be issued or delivered pursuant to the Plan or any Award, and the Committee shall determine whether cash or other securities shall be
paid or transferred in lieu of any fractional Shares, or whether such fractional Shares or any rights thereto shall be canceled, terminated
or otherwise eliminated.

 

(k) Awards may be granted to Participants
who are non-United States nationals or employed or providing services outside the United States, or both, on such terms and
conditions different from those applicable to Awards to Participants who are employed or providing services in the United States
as may, in the judgment of the Committee, be necessary or desirable to recognize differences in local law, tax policy or custom. The Committee
also may impose conditions on the exercise or vesting of Awards in order to minimize the Company’s obligation with respect to tax
equalization for Participants on assignments outside their home country.

 

Section 16. Effective
Date of the Plan. The Plan shall be effective as of the Effective Date.

 

Section 17. Term of
the Plan. No Award shall be granted under the Plan after the earliest to occur of (i) the 10-year anniversary
of September 21, 2021; (ii) the maximum number of Shares available for issuance under the Plan have been issued; or (iii) the
Board terminates the Plan in accordance with Section 14(a). However, unless otherwise expressly provided in the Plan or in an applicable
Award Agreement, any Award theretofore granted may extend beyond such date, and the authority of the Committee to amend, alter, adjust,
suspend, discontinue or terminate any such Award, or to waive any conditions or rights under any such Award, and the authority of the
Board to amend the Plan, shall extend beyond such date.

 

    14

     

    

 

Section 18. Cancellation
or “Clawback” of Awards.

 

(a) The Committee may specify in
an Award Agreement that a Participant’s rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation,
forfeiture or recoupment upon the occurrence of certain specified events, in addition to any otherwise applicable vesting or performance
conditions of an Award. Such events may include a Termination of Service with or without Cause (and, in the case of any Cause that is
resulting from an indictment or other non-final determination, the Committee may provide for such Award to be held in escrow or abeyance
until a final resolution of the matters related to such event occurs, at which time the Award shall either be reduced, cancelled or forfeited
(as provided in such Award Agreement) or remain in effect, depending on the outcome), violation of material policies, breach of non-competition,
non-solicitation, confidentiality or other restrictive covenants, or requirements to comply with minimum share ownership requirements,
that may apply to the Participant, or other conduct by the Participant that is detrimental to the business or reputation of the Company
and/or its Affiliates.

 

(b) The Committee shall have full
authority to implement any policies and procedures necessary to comply with Section 10D of the Exchange Act and any rules
promulgated thereunder and any other regulatory regimes. Notwithstanding anything to the contrary contained herein, any Awards granted
under the Plan (including any amounts or benefits arising from such Awards) shall be subject to any clawback or recoupment arrangements
or policies the Company has in place from time to time and the Committee may, to the extent permitted by applicable law and stock exchange
rules or by any applicable Company policy or arrangement, and shall, to the extent required, cancel or require reimbursement of any Awards
granted to the Participant or any Shares issued or cash received upon vesting, exercise or settlement of any such Awards or sale of Shares
underlying such Awards.

 

Section 19. Section 409A
of the Code. With respect to Awards subject to Section 409A of the Code, the Plan is intended to comply with the requirements
of Section 409A of the Code, and the provisions of the Plan and any Award Agreement shall be interpreted in a manner that satisfies
the requirements of Section 409A of the Code, and the Plan shall be operated accordingly. If any provision of the Plan or any term
or condition of any Award would otherwise frustrate or conflict with this intent, the provision, term or condition shall be interpreted
and deemed amended so as to avoid this conflict. Notwithstanding anything in the Plan to the contrary, if the Board considers a Participant
to be a “specified employee” under Section 409A of the Code at the time of such Participant’s “separation
from service” (as defined in Section 409A of the Code), and any amount hereunder is “deferred compensation” subject
to Section 409A of the Code, any distribution of such amount that otherwise would be made to such Participant with respect to an
Award as a result of such “separation from service” shall not be made until the date that is six months after such “separation
from service,” except to the extent that earlier distribution would not result in such Participant’s incurring interest or
additional tax under Section 409A of the Code. If an Award includes a “series of installment payments” (within the meaning
of Section 1.409A-2(b)(2)(iii) of the Treasury Regulations), a Participant’s right to such series of installment payments
shall be treated as a right to a series of separate payments and not as a right to a single payment, and if an Award includes “dividend
equivalents” (within the meaning of Section 1.409A-3(e) of the Treasury Regulations), a Participant’s right to such dividend
equivalents shall be treated separately from the right to other amounts under the Award. Notwithstanding the foregoing, the tax treatment
of the benefits provided under the Plan or any Award Agreement is not warranted or guaranteed, and in no event shall the Company be liable
for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by a Participant on account of non-compliance with
Section 409A of the Code.

 

Section 20. Successors
and Assigns. The terms of the Plan shall be binding upon and inure to the benefit of the Company and any successor entity, including
any successor entity contemplated by Section 12(c).

 

Section 21. Data Protection.
In connection with the Plan, the Company may need to process personal data provided by the Participant to the Company or its Affiliates,
third party service providers or others acting on the Company’s behalf. Examples of such personal data may include, without limitation,
the Participant’s name, account information, social security number, tax number and contact information. The Company may process
such personal data in its legitimate business interests for all purposes relating to the operation and performance of the Plan, including
but not limited to:

 

(a) administering and maintaining
Participant records;

 

(b) providing the services described
in the Plan;

 

    15

     

    

 

(c) providing information to future
purchasers or merger partners of the Company or any Affiliate, or the business in which such Participant works; and

 

(d) responding to public authorities,
court orders and legal investigations, as applicable.

 

The Company may share the Participant’s
personal data with (i) Affiliates, (ii) trustees of any employee benefit trust, (iii) registrars,
(iv) brokers, (v) third party administrators of the Plan, (vi) third party service providers acting
on the Company’s behalf to provide the services described above or (vii) regulators and others, as required by law.

 

If necessary, the Company may transfer
the Participant’s personal data to any of the parties mentioned above in a country or territory that may not provide the same protection
for the information as the Participant’s home country. Any transfer of the Participant’s personal data to recipients in a
third country will be made subject to appropriate safeguards or applicable derogations provided for under applicable law. Further information
on those safeguards or derogations can be obtained through the contact set forth in the Employee Privacy Notice (the “Employee Privacy
Notice”) that previously has been provided by the Company or its applicable Affiliate to the Participant. The terms set forth in
this Section 21 are supplementary to the terms set forth in the Employee Privacy Notice (which, among other things, further describes
the rights of the Participant with respect to the Participant’s personal data); provided that, in the event of any conflict between
the terms of this Section 21 and the terms of the Employee Privacy Notice, the terms of this Section 21 shall govern and control
in relation to the Plan and any personal data of the Participant to the extent collected in connection therewith.

 

The Company will keep personal
data collected in connection with the Plan for as long as necessary to operate the Plan or as necessary to comply with any legal or regulatory
requirements.

 

A Participant has a right to (i) request
access to and rectification or erasure of the personal data provided, (ii) request the restriction of the processing of his
or her personal data, (iii) object to the processing of his or her personal data, (iv) receive the personal data
provided to the Company and transmit such data to another party, and (v) to lodge a complaint with a supervisory authority.

 

Section 22. Governing
Law. The Plan and each Award Agreement shall be governed by the laws of the State of Delaware, without application of the conflicts
of law principles thereof.

 

 

16Document

SECURITIES PURCHASE AGREEMENT
This Securities Purchase Agreement (this “Agreement”) is made and entered into as of March 30, 2022 (the “Effective Date”) by and among MedAvail Holdings, Inc., a Delaware corporation (the “Company”), and the purchasers listed on the signature pages hereto (each a “Purchaser” and together the “Purchasers”). Certain terms used and not otherwise defined in the text of this Agreement are defined in SECTION 9 hereof.
RECITALS
WHEREAS, the Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated by the United States Securities and Exchange Commission (the “Commission”) under the Securities Act; and
WHEREAS, the Company desires to sell to the Purchasers, and the Purchasers desire to purchase from the Company, shares of common stock, par value $0.001 per share (the “Common Stock”) at a purchase price equal to the Purchase Price (defined below), together with warrants, in substantially the form attached hereto as Exhibit A, to purchase up to that number of additional shares of Common Stock equal to fifty percent (50%) of the number of shares of Common Stock purchased by such Purchaser (rounded down to the nearest whole share) at an exercise price per share of $1.25 (the “Warrants”), each in accordance with the terms and provisions of this Agreement.
NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties and covenants herein contained, the parties hereto hereby agree as follows:
SECTION 1.Authorization of Securities.
1.01The Company has authorized the sale and issuance of shares of Common Stock (the “Shares”), the Warrants and the shares of Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”), on the terms and subject to the conditions set forth in this Agreement. The Shares and the Warrants sold hereunder at the Closing (as defined below), shall be referred to as the “Securities.”
SECTION 2.Sale and Purchase of the Securities.
2.01Closings. Upon the terms and subject to the conditions herein contained, the Company agrees to sell to each Purchaser, and each Purchaser agrees, severally and not jointly, to purchase from the Company, at either a first closing (the “First Closing”) to occur on or before April 4, 2022 (the “First Closing Date”) or a second closing (the “Second Closing” and together with the First Closing, each, a “Closing”) to occur on July 1, 2022 or promptly thereafter (the “Second Closing Date” and together with the First Closing Date, each, the “Closing Date”), that number of shares of Common Stock set forth opposite such Purchaser’s name on the Schedule of Purchasers attached as Schedule I under the heading “Shares of Common Stock” for the purchase price to be paid by each Purchaser set forth opposite such Purchaser’s name on the Schedule of Purchasers (registered in the name of such Purchaser or its nominee in accordance with its delivery instructions), together with corresponding Warrants exercisable for that number of Warrant Shares set forth on Schedule I under the heading “Warrant Shares”.
2.02Purchase Price; Delivery. At the Closing, each Purchaser will pay the applicable purchase price set forth opposite such Purchaser’s name on the Schedule of Purchasers by wire transfer of immediately available funds in accordance with wire 

instructions provided by the Company to the Purchasers on or prior to the Closing. Notwithstanding anything to the contrary set forth herein, upon request made by Purchaser to the Company, the Company shall provide Purchaser with evidence reasonably satisfactory to the Purchaser regarding its ownership of the Securities purchased at the Closing, such as (i) evidence from the Company’s transfer agent showing such Purchaser’s purchased Securities credited to such Purchaser’s book-entry account maintained by the transfer agent on and as of the Closing Date, or (ii) a stock certificate representing such Purchaser’s purchased Securities.
SECTION 3.Representations and Warranties of the Purchasers. Each Purchaser, severally and not jointly, represents and warrants to the Company and Cowen and Company, LLC (“Cowen”) that the statements contained in this SECTION 3 are true and correct as of the Effective Date, and will be true and correct as of the Closing Date:
3.01Validity. The execution, delivery and performance of this Agreement and the consummation by the Purchaser of the transactions contemplated hereby have been duly authorized by all necessary corporate, partnership, limited liability or similar actions, as applicable, on the part of such Purchaser. This Agreement has been duly executed and delivered by the Purchaser and constitutes a valid and binding obligation of the Purchaser, enforceable against it in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.
3.02Brokers. There is no broker, investment banker, financial advisor, finder or other person which has been retained by or is authorized to act on behalf of the Purchaser who might be entitled to any fee or commission for which the Company will be liable in connection with the execution of this Agreement and the consummation of the transactions contemplated hereby.
3.03Investment Representations and Warranties. The Purchaser understands and agrees that the offering and sale of the Securities has not been registered under the Securities Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions for transactions not involving a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed herein.
3.04Acquisition for Own Account. The Purchaser is acquiring the Securities for its own account for investment and not with a view towards distribution in a manner which would violate the Securities Act or any applicable state or other securities laws without prejudice, however, to such Purchaser’s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities laws.  Nothing contained herein shall be deemed a representation or warranty by any Purchaser to hold the Securities for any period of time. The Purchaser is not party to any agreement providing for or contemplating the distribution of any of the Securities in a manner which would violate the Securities Act or any applicable state or other securities laws.
3.05No General Solicitation. The Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement. The purchase of the Securities has not been 
2

solicited by or through anyone other than the Company or Cowen on behalf of the Company.
3.06Ability to Protect Its Own Interests and Bear Economic Risks. The Purchaser has the capacity to protect its own interests in connection with the transactions contemplated by this Agreement and is capable of evaluating the merits and risks of the investment in the Securities. The Purchaser is able to bear the economic risk of an investment in the Securities.
3.07Accredited Investor; No Bad Actor. The Purchaser is an “accredited investor” as that term is defined in Rule 501(a) under the Securities Act. To the extent the Purchaser is a “Company Covered Person”: (i) the Purchaser has not taken any of the actions set forth in, and is not subject to, the disqualification provisions of Rule 506(d)(1) of the Securities Act; and (ii) neither the Purchaser nor, to the knowledge of the Purchaser, any of its directors, executive officers, other officers that may serve as a director or officer of any company in which it invests, general partners or managing members is subject to any Disqualification Events, except for Disqualification Events covered by Rule 506(d)(2)(ii)-(iii) or (d)(3) under the Securities Act. 
3.08Access to Information. The Purchaser has been given access to Company documents, records, and other information, and has had adequate opportunity to ask questions of, and receive answers from, the Company’s officers, employees, agents, accountants and representatives concerning the Company’s business, operations, financial condition, assets, liabilities and all other matters relevant to its investment in the Securities. Purchaser understands that an investment in the Securities bears significant risk.  The Purchaser understands that Cowen has acted solely as the agent of the Company in this placement of the Securities and such Purchaser has not relied on the business or legal advice of Cowen or any of its agents, counsel or affiliates in making its investment decision hereunder, and confirms that none of such persons has made any representations or warranties to such Purchaser in connection with the transactions contemplated hereunder and hereby.
3.09Restricted Securities. The Purchaser understands that the Securities will be characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a private placement under Section 4(a)(2) of the Securities Act and that under such laws and applicable regulations such Securities may be resold without registration under the Securities Act only in certain limited circumstances.
3.10Tax Advisors. The Purchaser has had the opportunity to review with the Purchaser’s own tax advisors the federal, state and local tax consequences of its purchase of the Securities set forth opposite such Purchaser’s name on the Schedule of Purchasers, where applicable, and the transactions contemplated by this Agreement. The Purchaser is relying solely on the Purchaser’s own determination as to tax consequences or the advice of such tax advisors and not on any statements or representations of the Company or any of its agents and understands that, except as otherwise provided herein, the Purchaser (and not the Company) shall be responsible for the Purchaser’s own tax liability that may arise as a result of the transactions contemplated by this Agreement.
3.11Short Sales. Other than consummating the transactions contemplated hereunder, the Purchaser has not directly or indirectly, nor has any individual or entity acting on behalf of or pursuant to any understanding with the Purchaser, executed any purchases or sales, including Short Sales (as defined below), of the securities of the Company during the period commencing at the time Purchaser was first contacted by the Company or any other individual or entity representing the Company regarding the 
3

transactions contemplated hereunder through the Effective Date. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers do not communicate or share information with, and have no direct knowledge of the investment decisions made by, the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall only apply with respect to the portion of assets manage by, the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. The Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction) except as otherwise required by applicable law or where disclosure is made to its affiliates and its and their employees, representatives, advisors or agents in connection with this transaction. Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. For purposes of this Agreement, “Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). For the avoidance of doubt, nothing contained herein shall prohibit a Purchaser from engaging in (i) any purchase of securities by Purchaser, its controlled affiliates or any person or entity acting on behalf of Purchaser or any of its controlled affiliates in an open market transaction after the execution of this Agreement, (ii) any sale of securities of the Company purchased by Purchaser, its controlled affiliates or any person or entity acting on behalf of Purchaser or any of its controlled affiliates in an open market transaction after the execution of this Agreement, or (iii) ordinary course, non-speculative hedging transactions.
SECTION 4.Representations and Warranties by the Company. The Company represents and warrants to the Purchasers and Cowen that the statements contained in this SECTION 4 are true and correct as of the Effective Date, and will be true and correct as the Closing Date (other than the representations and warranties that speak as of a specific date, which shall be made as of such date), except as set forth in the SEC Reports (but excluding any disclosures of risks set forth under the heading “Risk Factors”, disclosures of risks set forth in any “forward-looking statements” disclaimer or in any other statements that are similarly cautionary or predictive in nature) or in the disclosure schedules delivered by the Company to the Purchasers on the Effective Date as attached as Schedule II (the “Disclosure Schedule”):
4.01Organization, Good Standing, Corporate Power and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware.  The Company has the requisite corporate power and authority to own and operate its properties and assets, to carry on its business as presently conducted and as proposed to be conducted, to execute and deliver this Agreement, and to issue and sell the Securities listed on Schedule I under the First Closing, and subject to the approval by the Company’s stockholders of the Share Increase Proposal (as defined below) and the amendment of the Company’s certificate of incorporation in order to increase the authorized number of shares of Common Stock as may be necessary to issue the Shares and the Warrant Shares in the Second Closing, to issue and sell the Securities listed on Schedule I under the Second Closing, and to perform its obligations pursuant to this Agreement.  The Company is presently qualified to do business as a foreign corporation in each jurisdiction where the failure to be so qualified could reasonably be expected to have a Material Adverse Effect.   
4

4.02Subsidiaries. The Company does not own or control, directly or indirectly, any interest in any corporation, partnership, limited liability company, association or other business entity.
4.03Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not, in the previous twelve (12) months, received (i) written notice from the Nasdaq Stock Market LLC that the Company is not in compliance with the listing or maintenance requirements of the Nasdaq Stock Market LLC  that would result in immediate delisting or (ii) any notification, staff delisting determination, or public reprimand letter that requires a public announcement by the Company of any noncompliance or deficiency with respect to such listing or maintenance requirements. The Company is in compliance with all listing and maintenance requirements of the Nasdaq Stock Market LLC on the date hereof.
4.04Capitalization. 
(a)As of the Effective Date, the authorized capital stock of the Company consists of 100,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock, par value $0.001 per share (“Preferred Stock”).  As of December 31, 2021, the Company had 32,902,048 shares of Common Stock and no shares of Preferred Stock issued and outstanding.  Since December 31, 2021, no shares of Common Stock or Preferred Stock have been issued by the Company other than pursuant to the exercise of an option to purchase Common Stock granted under the Stock Plans (as defined below) or as a result of vesting of a restricted stock unit under the Stock Plans. As of the Effective Date, the Common Stock and the Preferred Stock have the rights, preferences, privileges and restrictions set forth in the Amended and Restated Certificate of Incorporation of the Company (the “Restated Certificate”).
(b)As of the Effective Date, the Company has reserved 7,952,083 shares of Common Stock for issuance to officers, directors, employees and consultants of the Company pursuant to its equity incentive plans and an employee stock purchase plan duly adopted by the Board and approved by the Company stockholders (the “Stock Plans”).  Since December 31, 2021no shares have been issued pursuant to exercises of options granted under the Stock Plans, options to purchase 2,924,339 shares of Common Stock have been granted and options to purchase 6,575,777 shares of Common Stock are currently outstanding, and 1,376,306 shares of Common Stock remain available for issuance to officers, directors, employees and consultants pursuant to the Stock Plans.
(c)Except for the securities and rights described in Subsection 4.03(b) of this Agreement and Subsection 4.04(c) of the Disclosure Schedule, and other than the transactions contemplated by this Agreement, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the Company any shares of Common Stock or Preferred Stock, or any securities convertible into or exchangeable for shares of Common Stock or Preferred Stock.
(d)As of the Effective Date, the outstanding shares have been duly authorized and validly issued in compliance with applicable laws, and are fully paid and nonassessable. The Company has reserved the Securities for issuance pursuant to this Agreement to be sold in the First Closing (and any Warrant Shares underlying Warrants issued at the First Closing) and subject to the approval by the Company’s stockholders of the Share Increase Proposal and the amendment of the Company’s certificate of incorporation in order to increase the authorized 
5

number of shares of Common Stock as may be necessary to issue the Shares and the Warrant Shares in the Second Closing, will reserve the Securities for issuance pursuant to this Agreement to be sold in the Second Closing (and any Warrant Shares underlying Warrants issued at the Second Closing).
(e)As of the Effective Date, all issued and outstanding shares of the Company’s Common Stock (i) have been duly authorized and validly issued and are fully paid and nonassessable, (ii) were issued in compliance with all applicable state and federal laws concerning the issuance of securities and (iii) were not issued in violation of any pre-emptive or similar rights.
(f)The Securities to be sold in the First Closing, when issued and delivered and paid for in compliance with the provisions of this Agreement, the Warrant Shares underlying the Warrants issued at the First Closing, when issued and delivered and paid for in compliance with the provisions of the applicable Warrant, and subject to the approval by the Company’s stockholders of the Share Increase Proposal and the amendment of the Company’s certificate of incorporation in order to increase the authorized number of shares of Common Stock as may be necessary to issue the Shares and the Warrant Shares in the Second Closing, the Securities to be sold in the Second Closing, when issued and delivered and paid for in compliance with the provisions of this Agreement, and the Warrant Shares underlying the Warrants issued at the Second Closing, when issued and delivered and paid for in compliance with the provisions of the applicable Warrant, will be duly authorized, validly issued, fully paid and nonassessable and issued in compliance with all applicable state and federal laws concerning the issuance of securities.  The Securities will be free of any liens or encumbrances, other than any liens or encumbrances created by or agreed to in writing by the Purchasers; provided, however, that the Securities are subject to restrictions on transfer under U.S. state and/or federal securities laws and as set forth herein.  
4.05Authorization. Subject to the approval by the Company’s stockholders of the Share Increase Proposal and the amendment of the Company’s certificate of incorporation in order to increase the authorized number of shares of Common Stock as may be necessary to issue the Shares and the Warrant Shares in the Second Closing, all corporate action on the part of the Company and its directors, officers and stockholders necessary for the authorization, execution and delivery of this Agreement by the Company, the authorization, sale, issuance and delivery of the Securities, and the performance of all of the Company’s obligations under this Agreement has been taken or will be taken prior to the First Closing or the Second Closing, as applicable.  This Agreement, when executed and delivered by the Company, shall constitute valid and binding obligations of the Company, enforceable in accordance with their terms, except (i) as limited by laws of general application relating to bankruptcy, insolvency and the relief of debtors, (ii) as limited by rules of law governing specific performance, injunctive relief or other equitable remedies and by general principles of equity, and (iii) to the extent the indemnification provisions contained in this Agreement may further be limited by applicable laws and principles of public policy.
4.06Bad Actor. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s Knowledge, any Company Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3), is applicable.  
4.07Financial Statements. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.  Such financial statements have been prepared in accordance 
6

with United States generally accepted accounting principles (“GAAP”), applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial condition of the Company as of and for the dates thereof and its results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
4.08Changes. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof:  
(a)there has been no event, occurrence or development that has had or that could reasonably be expected to have a Material Adverse Effect;
(b)the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission; 
(c)the Company has not altered its method of accounting or changed its principal registered public accounting firm; 
(d)the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock;
(e)there has not been any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the Company; 
(f)there has not been any waiver, not in the ordinary course of business, by the Company of a material right or of a material debt owed to it; 
(g)there has not been any satisfaction or discharge of a material lien, claim or encumbrance or payment of any obligation by the Company, except in the ordinary course of business; 
(h)other than the contemplated amendment to the Company’s certificate of incorporation pursuant to the Share Increase Proposal following approval by the Company’s stockholders, there has not been any change or amendment to the Restated Certificate or Bylaws, or termination of or material amendment to any material contract; 
(i)there has not been any material labor difficulties or, to the Company’s Knowledge, labor union organizing activities with respect to employees of the Company; 
7

(j)there has not been any material transaction entered into by the Company other than in the ordinary course of business; 
(k)there has not been a loss of the services of any executive officer (as defined in Rule 405 under the Securities Act) of the Company. 
4.09Intellectual Property. The Company and its subsidiaries own or possess the valid right to use all (i) patents, patent applications, trademarks, trademark registrations, service marks, service mark registrations, Internet domain name registrations, copyrights, copyright registrations, licenses, trade secret rights (“Intellectual Property Rights”) and (ii) inventions, software, works of authorships, trademarks, service marks, trade names, formulae, know how, Internet domain names and other intellectual property (including trade secrets and other unpatented and/or unpatentable proprietary confidential information, systems, or procedures) (collectively, "Intellectual Property Assets") necessary to conduct their respective businesses as currently conducted or as described to be conducted in the SEC Reports. The Company and its subsidiaries have not received written notice of any challenge by any other person to the rights of the Company and its subsidiaries with respect to any Intellectual Property Rights or Intellectual Property Assets owned or used by the Company or its subsidiaries. To the knowledge of the Company, the Company and its subsidiaries’ respective businesses as now conducted do not give rise to any infringement of, any misappropriation of, or other violation of, any valid and enforceable Intellectual Property Rights of any other person.  All licenses for the use of the Intellectual Property Rights described in the SEC Reports are valid, binding upon, and enforceable by or against the parties thereto in accordance with its terms.  The Company has no reason to believe that the licensors under such licenses and other agreements do not have and/or did not have all requisite power and authority to grant the rights to the Intellectual Property purported to be granted thereby.  The Company has complied in all material respects with, and is not in material breach nor has received any asserted or threatened claim of breach of any Intellectual Property license, and the Company has no knowledge of any breach or anticipated breach by any other person to any Intellectual Property license.  No claim has been made against the Company alleging the infringement by the Company of any patent, trademark, service mark, trade name, copyright, trade secret, license in or other intellectual property right or franchise right of any person.  The Company has taken all reasonable steps to protect, maintain and safeguard its Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements.  The consummation of the transactions contemplated by this Agreement will not result in the loss or impairment of or payment of any additional amounts with respect to, nor require the consent of any other person in respect of, the Company's right to own, use, or hold for use any of the Intellectual Property Rights as owned, used or held for use in the conduct of the business as currently conducted.  
4.10Proprietary Information and Invention Assignment. Each current and former consultant to the Company has entered into an agreement containing appropriate confidentiality and invention assignment provisions. To the knowledge of the Company, no officer, employee or consultant of the Company is in violation of such confidential information and invention assignment agreement or any prior employee contract or proprietary information agreement with any other corporation or third party.  
4.11Title to Properties and Assets; Liens. The Company has good and marketable title to its properties and assets, and has good title to all its leasehold interests, in each case, subject to no material mortgage, pledge, lien, lease, encumbrance or charge, other than (i) liens for current taxes not yet due and payable, (ii) liens imposed by law 
8

and incurred in the ordinary course of business for obligations not past due, (iii) liens in respect of pledges or deposits under workers’ compensation laws or similar legislation, and (iv) liens, encumbrances and defects in title which do not in any case materially detract from the value of the property subject thereto or, individually or in the aggregate, have, or would be reasonably expected to have, a Material Adverse Effect.  With respect to the property and assets it leases, the Company is in compliance with such leases in all material respects and holds a valid leasehold interest free of any liens, claims or encumbrances, subject to clauses (i)-(iv) above. All facilities, machinery, equipment, fixtures, vehicles and other properties owned, leased or used by the Company are in good operating condition and repair and are reasonably fit and usable for the purposes for which they are being used.
4.12Compliance with Other Instruments. The Company is not in violation of any of its certificate of incorporation or bylaws, each as amended to date, or of any term or provision of any mortgage, indebtedness, indenture, contract, agreement, instrument, judgment, order or decree to which it is party or by which it is bound, where such violation which could reasonably be expected to have a Material Adverse Effect.  The Company is not in violation of any federal or state statute, rule or regulation applicable to the Company, the violation of which could reasonably be expected to have a Material Adverse Effect. The execution and delivery of this Agreement by the Company, the performance by the Company of its obligations pursuant to this Agreement, and the issuance of the Securities, will not result in any violation of, or conflict with, or constitute a default under, the Company’s certificate of incorporation or bylaws, each as amended to date, any of the Company’s material agreements, nor result in the creation of any material mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the Company.
4.13Litigation. There are no actions, suits, proceedings or investigations pending against the Company or its properties (nor has the Company received written notice of any threat thereof) before any court or governmental agency that questions the validity of this Agreement or the ability of the Company to enter into them, or the ability of the Company to perform its obligations contemplated hereby and thereby, or that, either individually or in the aggregate, if determined adversely to the Company, would or could reasonably be expected to have a Material Adverse Effect or result in any change in the current equity ownership of the Company.  The Company is not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality.  There is no action, suit or proceeding initiated by the Company currently pending or which the Company currently intends to initiate.
4.14Governmental Consent. No consent, approval or authorization of or designation, declaration or filing with any governmental authority on the part of the Company is required in connection with the valid execution and delivery of this Agreement, or the offer, sale or issuance of the Securities, or the consummation of any other transaction contemplated by this Agreement, except (i) the continued effectiveness of the Restated Certificate with the office of the Secretary of State of the State of Delaware, as may be amended to increase the authorized number of shares of Common Stock to cover the Securities to be issued pursuant to this Agreement in connection with the Share Increase Proposal, (ii) the filing of such notices as may be required under the Securities Act, (iii) such filings as may be required under applicable state securities laws, which will be timely filed within the applicable periods therefor, and (iv) consents that have been obtained, or will be obtained, pursuant to the rules and regulations of Nasdaq, including a Nasdaq Listing of Additional Shares notification form.
9

4.15Permits. The Company has all franchises, permits, licenses, and any similar authority necessary for the conduct of its business as now being conducted by it, the lack of which would have a Material Adverse Effect, and reasonably believes it can obtain, without undue burden or expense, any similar authority for the conduct of its business as presently planned to be conducted.  The Company is not in default in any material respect under any of such franchises, permits, licenses or other similar authority.
4.16Offering. Subject to the accuracy of the Purchasers’ representations and warranties in Section 3, the offer, sale and issuance of the Securities to be issued in conformity with the terms of this Agreement constitute transactions exempt from the registration requirements of the Securities Act and from the registration or qualification requirements of applicable state securities laws. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3, none of the Company, its subsidiaries nor, to the Company’s Knowledge, any of its affiliates or any person acting on its behalf has, directly or indirectly, at any time within the past six (6) months, made any offers or sales of any Company security or solicited any offers to buy any security under circumstances that would (i) eliminate the availability of the exemption from registration under the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii) cause the offer and sale of the Securities pursuant to this Agreement to be integrated with prior offerings by the Company for purposes of any applicable law, regulation or stockholder approval provisions.  Neither the Company nor, to the Company's Knowledge, any Person acting on behalf of the Company has offered or sold any of the Securities by any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any seminar or any other form of general solicitation or general advertising.
4.17Registration and Voting Rights. (i) Other than as set forth in the Registration Rights Agreement (as defined below), the Company is presently not under any obligation and has not granted any rights to register under the Securities Act any of its presently outstanding securities or any of its securities that may hereafter be issued; (ii) to the Company’s Knowledge, no stockholder of the Company has entered into any agreements with respect to the voting of capital shares of the Company; and (iii) other than the right to repurchase stock from its employees, consultants and other service providers pursuant to contractual rights of repurchase in connection with the cessation of services to the Company, the Company is not a party to any buy-sell agreements, option or right of first purchase agreements or other similar agreements of any kind with respect to sales of the Company’s securities.
4.18Brokers or Finders. Except as set forth in the Engagement Letter (as defined below), the Company has not incurred, and will not incur, directly or indirectly, as a result of any action taken by the Company, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with this Agreement or any of the transactions contemplated hereby or any prior issuances of Company stock or warrants. There is no broker, investment banker, financial advisor, finder or other person which has been retained by or is authorized to act on behalf of the Company who might be entitled to any fee or commission for which the Purchaser will be liable in connection with the execution of this Agreement and the consummation of the transactions contemplated hereby.
4.19Tax Returns and Payments. The Company has timely filed all tax returns required to be filed by it with appropriate federal, state and local governmental agencies.  These returns and reports are true and correct in all material respects.  All taxes shown to 
10

be due and payable on such returns, any assessments imposed, and, to the Company’s Knowledge, all other taxes due and payable by the Company on or before the Closing have been paid or will be paid prior to the time they become delinquent.  The Company has not been advised in writing (i) that any of its returns have been or are being audited as of the date hereof, or (ii) of any deficiency in assessment or proposed judgment with respect to its federal, state or local taxes. Notwithstanding anything herein to the contrary, the Company shall pay all transfer agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by the Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchaser other than income and capital gains taxes of the Purchaser that may be incurred in connection with the transactions contemplated hereby.
4.20Real Property Holding Corporation. The Company is not a “real property holding corporation” within the meaning of Section 897(c)(2) of the Internal Revenue Code of 1986, as amended.
4.21Employees.
(a)To the Company’s Knowledge, there are no strikes, labor disputes or union organization activities pending or threatened between it and its employees.  To the Company’s Knowledge, none of its employees belongs to any union or collective bargaining unit.  
(b)The Company has entered into its standard form of employment agreement with each of its employees, its standard form of consulting agreement with each of its consultants. The Company is not aware that any officer or key employee intends to terminate his or her employment with the Company. 
(c)The Company is not delinquent in payments to any of its employees, consultants or independent contractors for any wages, salaries, commissions, bonuses or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants or independent contractors.  The Company has complied in all material respects with all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker classification and collective bargaining.  The Company has withheld and paid to the appropriate governmental entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from employees of the Company and is not liable for any arrears of wages, taxes, penalties or other sums for failure to comply with any of the foregoing.
4.22Employee Benefit Plans. The Company has complied in all material respects with all applicable laws for and the terms of each employee benefit plan maintained, established or sponsored by the Company, or which the Company participates in or contributes to, which is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).  The Company believes in good faith that any “nonqualified deferred compensation plan” (as such term is defined under Section 409A(d)(1) of the Code and the guidance thereunder) under which the Company makes, is obligated to make or promises to make, payments complies in all material respects, in both form and operation, with the requirements of Section 409A of the Code and the guidance thereunder.
4.23Obligations to Related Parties. No employee, officer, director or, to the Company’s Knowledge, member of his or her immediate family is indebted to the 
11

Company, nor is the Company indebted (or committed to make loans or extend or guarantee credit) to any of them other than (i) for payment of salary for services rendered, (ii) reimbursement for reasonable expenses incurred on behalf of the Company, and (iii) for other standard employee benefits made generally available to all employees (including stock option agreements outstanding under any stock option plan approved by the Company’s Board of Directors and stock purchase agreements approved by the Company’s Board of Directors).  To the Company’s Knowledge, no employee, officer, director or stockholder, nor any member of their immediate families, is, directly or indirectly, interested in any contract with the Company (other than such contracts as relate to any such person’s ownership of capital stock or other securities of the Company) that would be disclosable under Item 404 of Regulation S-K.
4.24Insurance. The Company has in full force and effect fire and casualty insurance policies in amounts customary for companies in similar businesses similarly situated. 
4.25Environmental and Safety Laws. The Company is not in material violation of any applicable statute, law, or regulation relating to the environment or occupational health and safety, and,  no material expenditures are or will be required in order to comply with any such existing statute, law, or regulation.
4.26Data Privacy. In connection with its collection, storage, transfer (including, without limitation, any transfer across national borders) and/or use (collectively, “Processing”) of any information defined as “personal information,” “personal data,” “protected health information” or any analogous terms under applicable law from any individuals, including, without limitation, as applicable, any customers, prospective customers, employees and/or other third parties (collectively, “Personal Information”), the Company is and has been in compliance in all material respects with (i) all applicable laws relating to privacy or data security, telephone and text message communications, and marketing by email or other channels, in all jurisdictions, (ii) the Company’s privacy policies, and (iii) the privacy and data security requirements of any contracts or codes of conduct to which the Company is a party.  The Company has commercially reasonable physical, technical, organizational and administrative security measures and policies in place to protect all Personal Information collected by it or on its behalf from and against unauthorized access, use and/or disclosure.  The Company is and has been in compliance in all material respects with all laws relating to data loss, theft and breach of security notification obligations, and, as required by HIPAA, the Company has entered into a business associate agreement (each a “BAA”) that complies with the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, as amended (“HIPAA”), in each case in which the Company (i) is acting as a business associate (as defined in 45 C.F.R. § 160.103) or (ii) provides access to protected health information to a third party.
4.27IT Systems.   There has been no material security breach or attack or other compromise of any of the Company’s information technology and computer systems, networks, hardware, software, data (including such data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of the Company), equipment or technology (“IT Systems and Data”). The Company has not been notified, and has no knowledge, of any security breach, attack or compromise of or to its IT Systems and Data, and the Company has complied, and is presently in compliance, in all material respects, with (A) all applicable laws, statutes and any legally binding judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, industry guidelines, standards, (B) all of the Company’s internal policies, and (C) and contractual obligations, each of (A)-(C) as related to the privacy and 
12

security of IT Systems and Data or to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification. The Company has implemented backup and disaster recovery technology.
4.28Foreign Corrupt Practices Act. Neither the Company nor any of its subsidiaries nor any of their respective directors, officers, employees or, to the Company’s Knowledge, agents have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), foreign political party or official thereof or candidate for foreign political office for the purpose of improperly (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order to assist the Company or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the Company nor any of its subsidiaries nor any of their respective directors, officers, employees or, to the Company’s Knowledge, agents have made or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. Neither the Company nor, to the Company’s Knowledge, any of its officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law (collectively, “Enforcement Action”).
4.29Export Control Laws. The Company has conducted all export transactions in accordance with applicable provisions of United States export control laws and regulations, including the Export Administration Regulations, the International Traffic in Arms Regulations, the regulations administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”), and the export control laws and regulations of any other applicable jurisdiction. Without limiting the foregoing: (a) the Company has obtained all export licenses and other approvals, timely filed all required filings and has assigned the appropriate export classifications to all products, in each case as required for its exports of products, software and technologies from the United States and any other applicable jurisdiction; (b) the Company is in compliance with the terms of all applicable export licenses, classifications, filing requirements or other approvals; (c) there are no pending or, to the Knowledge of the Company, threatened claims against the Company with respect to such exports, classifications, required filings or other approvals; (d) there are no pending investigations related to the Company’s exports; and (e) there are no actions, conditions, or circumstances pertaining to the Company’s export transactions that would reasonably be expected to give rise to any material future claims.  The Company will not directly or indirectly use the proceeds of the offering of the Securities contemplated hereby, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person or entity for the purpose of financing the activities of any Person that is the target of sanctions administered or enforced by such authorities or in connection with any country or territory that is the target of country-wide or territory-wide OFAC sanctions (currently, Iran, Syria, Cuba, North Korea, and the Crimea Region of Ukraine). None of the Company’s directors, officers, employees, or, to the Company’s Knowledge, agents acting on the Company’s behalf, is the target of OFAC sanctions or is subject to debarment or any list-based designations under U.S. export control laws and regulations, including U.S. sanctions.  
4.30CFIUS. The Company has conducted an assessment and determined that the Company does not (a) produce, design, test, manufacture, fabricate, or develop 
13

“critical technologies” as that term is defined in 31 C.F.R. § 800.215; (b) perform the functions as set forth in column 2 of Appendix A to 31 C.F.R. part 800 with respect to covered investment “critical infrastructure”; or (c) to the Company’s Knowledge, maintain or collect, directly or indirectly, “sensitive personal data” as that term is defined in 31 C.F.R. § 800.241.
4.31Investment Company Status.  Neither the Company nor any of its Affiliates is, and immediately after the issuance and sale of the Securities hereunder and the application of the net proceeds from such issuance and sale, none of the Company nor any of its Affiliates will be, required to be registered as an “investment company” under the Investment Company Act of 1940, as amended.
4.32Distribution Restrictions.  The Company is not currently prohibited, or as a result of the transactions contemplated by this Agreement, will not be prohibited, directly or indirectly, from making distributions with respect to its equity securities.
4.33SEC Reports. The Company has filed or furnished, as applicable, all reports, proxy statements, schedules, forms, statements, certifications and other documents (including exhibits and all other information incorporated by reference therein) required to be filed by the Company under the Securities Exchange Act of 1934, as amended (the “Exchange Act,” and such reports, proxy statements, schedules, forms, statements, certifications and other documents, the “SEC Reports”), for the two (2) years preceding the date hereof (or such shorter period since the Company was first required by law or regulation to file such material).
4.34Internal Controls.  The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) of the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by the Company’s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; the Company’s internal control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting; there has been no fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting; since the date of the latest audited financial statements included or incorporated by reference in the Company’s SEC Reports, there has been no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) of the Exchange Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that material information relating to the Company is made known to the Company’s principal executive officer and principal financial officer by others within those entities; such disclosure controls and procedures are effective. The Company is in compliance in all material respects with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated by the Commission thereunder.  The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the 
14

existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
4.35Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Common Stock, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, the Common Stock, or (iii) paid or agreed to pay to any person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), as set forth in Section 4.33 of the Disclosure Schedules.
4.36Healthcare Regulatory Proceedings.  There is no legal or governmental proceeding to which the Company or any of its subsidiaries is a party or of which any property or assets of the Company or any of its subsidiaries is the subject, including any proceeding before the U.S. Department of Health and Human Services (“HHS”), U.S. state boards of pharmacy or comparable federal, state, local or foreign governmental bodies; and to the Company’s knowledge after reasonable investigation and due diligence inquiry, no such proceedings are threatened by governmental or regulatory authorities or threatened by others.  The Company is in material compliance with all applicable federal, state, local and foreign laws, regulations, orders and decrees governing its business as prescribed by the HHS, or any other federal, state or foreign agencies or bodies engaged in the regulation of the Company’s business.  Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority.  Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or, to the Company’s knowledge, any agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. 
4.37Regulatory Matters. The Company has not received any correspondence or notice from any court or arbitrator or federal, state, local, or foreign governmental or regulatory authority, alleging or asserting noncompliance with the Health Care Laws (as defined below).  The Company and its directors, officers, employees and, to the Company’s knowledge, agents are and have been in material compliance with all applicable health care laws, including without limitation, the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §301 et seq.), the Controlled Substances Act (21 U.S.C. § 801 et seq.), the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), the civil False Claims Act (31 U.S.C. § 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. § 17921 et seq.) the exclusions law (42 U.S.C. § 1320a-7), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, and the regulation promulgated pursuant to such laws, and comparable state laws, and all other local, state, federal, national, supranational, and foreign laws relating to the practice or delivery of pharmacy and other health care or related services, or billing or reimbursement therefor, including without limitation, such laws regarding pharmacy facility and professional licensure, fraud and abuse, kickbacks, self-referrals, fee-splitting, false claims, and the regulation of the 
15

Company (collectively, “Health Care Laws”); provided, however, “Health Care Laws” shall not include Privacy Laws.   Neither the Company nor any of its officers, directors, employees, or, to the Company’s knowledge, any agents has been or is currently excluded from participation in the Medicare and Medicaid programs or any other state or federal health care program. Each healthcare professional contracted by the Company’s subsidiary to provide any pharmacy-related services for or on behalf of such subsidiary or its affiliated pharmacies, as applicable, including pharmacists and related personnel, was at the time of providing the clinical services duly licensed or authorized, as applicable, to practice his or her profession in the state where such clinical services were rendered, as applicable, and each healthcare professional that currently provides clinical services is duly licensed or authorized, as applicable, to practice his or her profession in the state in which healthcare professional is performing clinical services. To the Company’s knowledge, no event has occurred and no fact, circumstance or condition exists that has or reasonably may be expected to result in the denial, loss, suspension, revocation, rescission, probation or any other disciplinary action of or to any such professional license or authorization. No such healthcare professional during the performance of services for or on behalf of Company’s subsidiary, as applicable: (i) has been sanctioned or disciplined by any licensing board or any other governmental agency or body, (ii) has had a final judgment or settlement without judgment entered against him or her in connection with a malpractice claim, (iii) has been found liable or responsible for any civil offense reasonably related to qualifications or competence relating to his or her professional practice, and/or (iv) has been terminated for cause related to a violation of a Health Care Law.
4.38Disclosure Materials. The SEC Reports, as of the applicable date of filing, do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
4.39No More Favorable Terms.  The Company has not entered into any side letter or similar agreement with any other Purchaser in connection with the purchase of Securities hereunder that includes terms and conditions that are more advantageous to such person than Purchaser hereunder in respect of the purchase of the Securities.
SECTION 5.Covenants.
5.01Reasonable Best Efforts. Each party shall use its reasonable best efforts to satisfy each of the conditions to be satisfied by it as provided in SECTION 6 in accordance with the terms of this Agreement, including to amend the Company’s certificate of incorporation in connection with the Share Increase Proposal.
5.02Expenses. Except as otherwise provided elsewhere in this Agreement, the Company and each Purchaser is liable for, and will pay, its own expenses incurred in connection with the negotiation, preparation, execution and delivery of this Agreement, including, without limitation, attorneys’ and consultants’ fees and expenses.
5.03No Integration.  The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities to the Purchasers, or that will be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any trading market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.
16

5.04Acknowledgement of Irrevocable Proxy Grant. Reference is made to that certain Securities Purchase Agreement, dated as of October 9, 2020, by and among MedAvail, Inc., the Ally Bridge Group Purchasers and the other purchasers party thereto (the "Prior Agreement").  Pursuant to Section 5.05 of the Prior Agreement, from and after October 9, 2020 and until such time as the Ally Bridge Group Purchasers and their controlled Affiliates no longer own any shares of Common Stock (the “Proxy Period”), the Ally Bridge Group Purchasers irrevocably appointed as their proxy and attorney-in-fact the Company and any person designated in writing by the Company, each of them individually, with full power of substitution and resubstitution, to vote, in connection with any matters with respect to which stockholders of the Company cast votes of shares of Common Stock during such period, any and all shares of Common Stock held by the Ally Bridge Group Purchasers or their Affiliates that represent more than 9.99% of the consolidated voting power of all issued and outstanding shares of Common Stock held by all stockholders of the Company entitled to vote on such matters (and, for the avoidance of doubt, the proxy contemplated by this sentence was not be deemed granted with respect to any shares of Common Stock held by the Ally Bridge Group Purchasers and their controlled Affiliates that represent 9.99% or less of the consolidated voting power of all issued and outstanding shares of Common Stock held by all stockholders of the Company entitled to vote on such matters) (collectively, and as more specifically set forth in Section 5.05 of the Prior Agreement, the "Irrevocable Proxy Grant"). The Ally Bridge Group Purchasers hereby acknowledge and agree that (i) the Proxy Period is continuing and has not ended, (ii) the Irrevocable Proxy Grant remains in full force and effect and (iii) the shares of Common Stock purchased by the Ally Bridge Group Purchasers hereunder shall be subject to the Irrevocable Proxy Grant in all respects.  In addition, the Company acknowledges and agrees that Section 5.05 of the Prior Agreement remains in full force and effect, and the Company has assumed all rights and obligations of MedAvail, Inc. thereunder.
5.05Indemnification. The Company agrees to indemnify and hold harmless each Purchaser and its Affiliates, and their respective directors, officers, trustees, members, managers, employees, investment advisers, broker-dealers and agents, from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under this Agreement, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally judicially determined not to have resulted from such Person’s fraud or willful misconduct; provided, however, that the Company will not be liable in any such case to the extent that any such losses, claims, damages, liabilities and expenses arises out of or are based upon the inaccuracy of any representations made by such indemnified party in this Agreement, or the failure of such indemnified party to comply with the covenants and agreements contained herein. The liability of the Company under this paragraph shall not exceed the total Purchase Price paid by the Purchaser for the Securities hereunder.
5.06Conduct of Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense 
17

of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement.
5.07Share Increase Proposal. At the next meeting of the stockholders of the Company where there is a proposal to approve amending the Company’s certificate of incorporation in order to increase the authorized number of shares of Common Stock as may be necessary to issue the Shares and the Warrant Shares in the Second Closing (the “Share Increase Proposal”), and at every adjournment or postponement thereof, and on every action or approval by written consent or resolution of the stockholders of the Company with respect to the Share Increase Proposal, each Purchaser agrees that such Purchaser shall participate and vote all voting securities held by them or over which they exercise voting power, to approve the Share Increase Proposal.  Any such vote shall be cast (and each consent shall be given) by such Purchaser in accordance with such procedures relating thereto so as to ensure that it is duly counted, including for purposes of determining that a quorum is present and for purposes of recording the results of such vote or consent.  The Company shall further use commercially reasonable efforts to obtain stockholder approval for the Share Increase Proposal.
SECTION 6.Conditions of Obligations.
6.01Conditions of the Purchasers’ Obligations at the Closing. The obligations of the Purchasers under SECTION 2 hereof are subject to the fulfillment, at or prior to the Closing, of all of the following conditions, any of which may be waived in whole or in part by the Purchasers in writing in their absolute discretion.
(a)Representations and Warranties. The representations and warranties of the Company shall be true and correct in all respects on and as of the Closing Date with the same force and effect as if made on and as of the Closing Date (except to the extent such representations and warranties are specifically made on and as of a particular date, in which case such representations and warranties shall be true and correct as of such date).  
(b)Performance. The Company shall have performed and complied in all material respects with all covenants, agreements, obligations and conditions contained in this 
18

Agreement that are required to be performed or complied with by it on or prior to the Closing Date.
(c)Compliance Certificate. The Chief Executive Officer of the Company shall have delivered to the Purchasers at the Closing Date a certificate certifying that the conditions specified in Sections 6.01(a) and 6.01(b) of this Agreement have been fulfilled.
(d)Secretary’s Certificate. The Secretary of the Company shall have delivered to the Purchasers at the Closing Date a certificate certifying (i) the Restated Certificate, as amended, of the Company; (ii) the Bylaws of the Company; (iii) resolutions of the Board (or an authorized committee thereof) approving this Agreement and the transactions contemplated by this Agreement; and (iv) a certificate of good standing of the Company.
(e)Qualification under Securities Laws. All registrations, qualifications, permits and approvals, if any, required under applicable federal and state securities laws shall have been obtained for the lawful execution, delivery and performance of this Agreement.
(f)Opinion of Company Counsel. The Purchasers and Cowen shall have received from Wilson Sonsini Goodrich & Rosati, P.C., counsel for the Company, an opinion, dated as of the Closing Date, in substantially the form of Exhibit B attached to this Agreement.
(g)Registration Rights Agreement. The Company shall have delivered to the Purchasers that certain Registration Rights Agreement by and among the Company and the persons and entities set forth therein, to be dated as of the Closing, in substantially the form attached hereto as Exhibit C (the “Registration Rights Agreement”), duly executed by the Company.
(h)Amendment to Certificate of Incorporation. With respect to the Second Closing only, the Company shall have amended the Company’s certificate of incorporation in order to increase the authorized number of shares of Common Stock as may be necessary to issue all the Shares and the Warrant Shares.
(i)No Material Adverse Effect. No Material Adverse Effect shall have occurred that is continuing.
6.02Conditions of the Company’s Obligations. The obligations of the Company under SECTION 2 hereof are subject to the fulfillment, at or prior to the Closing, of all of the following conditions, any of which may be waived in whole or in part by the Company in its absolute discretion.
(a)Representations and Warranties. The representations and warranties of the Purchasers contained in this Agreement shall be true and correct in all material respects on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of the Closing Date (except to the extent expressly made as of an earlier date in which case as of such earlier date).
(b)Performance. Each Purchaser shall have performed and complied in all material respects with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or prior to the Closing Date.
(c)Qualification under or Exemption from Securities Laws. All registrations, qualifications, permits and approvals, if any, or exemptions therefrom, required under applicable 
19

federal and state securities laws shall have been, or will be, obtained for the lawful execution, delivery and performance of this Agreement.
(d)Registration Rights Agreement. Each Purchaser shall have delivered to the Company the Registration Rights Agreement, duly executed by such Purchaser.
(e)Amendment to Certificate of Incorporation. With respect to the Second Closing only, the Company shall have amended the Company’s certificate of incorporation in order to increase the authorized number of shares of Common Stock as may be necessary to issue all the Shares and the Warrant Shares.
SECTION 7.Transfer Restrictions; Restrictive Legend.
7.01Transfer Restrictions. The Purchasers understand that the Company may, as a condition to the transfer of any of the Securities prior to the commencement of the Effectiveness Period (as defined in the Registration Rights Agreement), require that the request for transfer be accompanied by a certificate and/or an opinion of counsel reasonably satisfactory to the Company, to the effect that the proposed transfer does not result in a violation of the Securities Act, unless such transfer is covered by an effective registration statement or by Rule 144 or Rule 144A or any other available exemption from the registration requirements under the Securities Act. The Company will not require such a legal opinion in any transactions in which a Purchaser transfers Securities to an Affiliate of such Purchaser; provided that each transferee agrees in writing to be subject to the terms of this Section 7.01. It is understood that the certificates evidencing the Securities may bear substantially the following legend prior to the commencement of the Effectiveness Period:
“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS OR A CERTIFICATE AND/OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED (SUBJECT TO CERTAIN EXCEPTIONS).”
SECTION 8.Registration, Transfer and Substitution of Certificates for Securities.
8.01Stock Register; Ownership of Securities. The Company will keep at its principal office, or will cause its transfer agent to keep, a register in which the Company will provide for the registration of transfers of the Securities. The Company may treat the person in whose name any of the Securities are registered on such register as the owner thereof and the Company shall not be affected by any notice to the contrary. All references in this Agreement to a “holder” of any Securities shall mean the person in whose name such Securities are at the time registered on such register. 
SECTION 9.Definitions. Unless the context otherwise requires, the terms defined in this SECTION 9 shall have the meanings specified for all purposes of this Agreement.
“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital fund, hedge fund or private equity fund now or hereafter existing that is 
20

controlled by, or under common control with, one or more general partners or managing members of, or shares the same management company with, such Person.
“Ally Bridge Group Purchasers” means ABG WTT-MedAvail Limited and Ally Bridge MedAlpha Master Fund L.P.
“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in the City of New York or the City of San Francisco are authorized or required by law to remain closed.
“Code” means the Internal Revenue Code of 1986, as amended.
“Company Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).
“Knowledge” including the phrase “to the Company’s Knowledge” shall mean with respect to any statement made to the knowledge of the Company, that statement is based upon the actual knowledge of an executive officer of the Company after due inquiry.
“Material Adverse Effect” means (a) a material adverse change in, or a material adverse effect on the Company’s financial condition, assets (including intangible assets), liabilities (actual or contingent) taken as a whole, business or operations of the Company as currently conducted or as currently proposed to be conducted or (b) a material impairment of the ability of the Company to perform its obligations under this Agreement.
“Nasdaq” means The Nasdaq Stock Market, LLC.
“Person” means any natural person, company, corporation, limited liability company, general partnership, limited partnership, trust, proprietorship, joint venture, business organization or governmental entity.
“Purchase Price” means the price per share of Common Stock that is equal to $1.0625.
“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
SECTION 10.Miscellaneous.
10.01Waivers and Amendments. Any term of this Agreement may be amended, waived (either generally or in a particular instance, either retroactively or prospectively and either for a specified period of time or indefinitely), discharged or terminated only by an instrument in writing executed by the Company and the Purchasers holding, or having the right to purchase at the Closing, a majority of the Securities purchased or to be purchased hereunder; provided, however, that if any amendment, waiver, discharge or termination operates in a manner that treats any Purchaser in a manner disparate from other Purchasers, the consent of such disparately treated Purchaser shall also be required for such amendment, waiver, discharge or termination.
21

10.02Notices. All notices, requests, consents, and other communications under this Agreement shall be in writing and shall be deemed delivered: (a) when delivered, if delivered personally, (b) four (4) Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid, (c) one (1) Business Day after being sent via a reputable nationwide overnight courier service guaranteeing next Business Day delivery, or (d) when receipt is acknowledged, in the case of email, in each case to the intended recipient as set forth below, with respect to the Company, and to the addresses set forth on the Schedule of Purchasers with respect to the Purchasers.
If to the Company:
MedAvail Holdings, Inc.
4720 E Cotton Gin Loop
Suite 200 
Phoenix, AZ 85040   
Attention: Mark Doerr and Ramona Seabaugh
with a copy (which shall not constitute notice) to:
Wilson Sonsini Goodrich & Rosati, P.C.
650 Page Mill Road
Palo Alto, CA 94304
Attention: Philip Oettinger and Eric Hsu
or at such other address as the Company or each Purchaser may specify by written notice to the other parties hereto in accordance with this Section 10.02.
10.03Cumulative Remedies. None of the rights, powers or remedies conferred upon the Purchasers on the one hand or the Company on the other hand shall be mutually exclusive, and each such right, power or remedy shall be cumulative and in addition to every other right, power or remedy, whether conferred by this Agreement or now or hereafter available at law, in equity, by statute or otherwise.
10.04Successors and Assigns. All the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective parties hereto, the successors and permitted assigns of each Purchaser and the successors of the Company, whether so expressed or not. None of the parties hereto may assign its rights or obligations hereof without the prior written consent of the Company in respect of a Purchaser or the relevant Purchaser in respect of the Company, except that a Purchaser may, without the prior consent of the Company, assign its rights to purchase the Securities hereunder to any of its Affiliates (provided each such Affiliate agrees to be bound by the terms of this Agreement and makes the same representations and warranties set forth in SECTION 3 hereof). This Agreement shall not inure to the benefit of or be enforceable by any other person.
10.05No Third-Party Beneficiaries. Other than Cowen, this Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person. The parties further agree that Cowen may rely on or, if Cowen so requests, be specifically named as an addressee of, the legal opinions to be delivered pursuant to this Agreement.
10.06Headings. The headings of the Sections and paragraphs of this Agreement have been inserted for convenience of reference only and do not constitute a part of this Agreement.
22

10.07Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to its conflict of law principles. Any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby may be brought in the state courts of Delaware and the United States District Court located in the State of Delaware, and each of the parties hereby consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding which is brought in any such court has been brought in an inconvenient forum. Process in any such suit, action or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court.
10.08Survival. The representations and warranties of the Purchasers and the Company contained in SECTION 3 and SECTION 4, and the agreements and covenants set forth in Sections 5, 7, 8 and 10 shall survive the Closing for a period of one year in accordance with their respective terms; provided however, that the representations and warranties of the Company set forth in Sections 4.01, 4.03 and 4.04 and the provisions of Sections 5.04 and 5.05 shall survive the Closing until the expiration of any statute of limitations under applicable law. Each Purchaser shall be responsible only for its own representations, warranties, agreements and covenants hereunder.
10.09Counterparts; Effectiveness. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, with the same effect as if all parties had signed the same document. All such counterparts (including counterparts delivered by facsimile or other electronic format) shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or by electronic transmission of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com). This Agreement shall become effective when each party hereto shall have received counterparts hereof signed by all of the other parties hereto.
10.10Entire Agreement. This Agreement (including the exhibits and schedules hereto), the Warrants and the Registration Rights Agreement (with respect to the Purchasers that are party thereto) constitute the entire agreement among the parties hereto with respect to the subject matter hereof and, except as set forth below, this agreement supersedes and replaces all other prior agreements, written or oral, among the parties hereto with respect to the subject matter hereof. Notwithstanding the foregoing or anything to the contrary in this Agreement, this Agreement shall not supersede any confidentiality or other non-disclosure agreements that may be in place between the Company and any Purchaser to the extent any such agreement has been entered into.
10.11Severability. If any provision of this Agreement shall be found by any court of competent jurisdiction to be invalid or unenforceable, the parties hereby waive such provision to the extent that it is found to be invalid or unenforceable. Such provision shall, to the maximum extent allowable by law, be modified by such court so that it becomes enforceable, and, as modified, shall be enforced as any other provision hereof, all the other provisions hereof continuing in full force and effect.
10.12Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under this Agreement are several and not joint with the 
23

obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as, and the Company acknowledges that the Purchasers do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group, and the Company will not assert any such claim with respect to such obligations or the transactions contemplated by this Agreement and the Company acknowledges that the Purchasers are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement. The Company acknowledges and each Purchaser confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.
10.13Termination. This Agreement shall terminate upon the occurrence of either of the following events:
(a)In the event that the First Closing is not consummated within two (2) weeks of the Effective Date, this Agreement shall automatically terminate.   
(b)Upon the mutual consent of the Company and the Purchasers. 
10.14Exculpation of Cowen. Each party hereto agrees for the express benefit of Cowen and its affiliates and representatives that:
(a)Neither Cowen nor any of its affiliates or any of their representatives (i) has any duties or obligations other than those specifically set forth herein or in the engagement letter, dated as of January 4, 2022, between the Company and Cowen (the “Engagement Letter”); (ii) shall be liable for any improper payment made in accordance with the information provided by the Company; (iii) makes any representation or warranty, or has any responsibilities as to the validity, accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement or in connection with any of the transactions contemplated hereby and thereby; or (iv) shall be liable (x) for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or powers conferred upon it by this Agreement or (y) for anything which any of them may do or refrain from doing in connection with this Agreement or any transactions contemplated hereby and thereby; in each case, absent its own gross negligence, fraud or willful misconduct.
(b)Cowen, its affiliates and their representatives shall be entitled to (i) rely on, and shall be protected in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to any of them by or on behalf of the Company, including the representations made by the Company and the Purchasers herein, and (ii) be indemnified by the Company for acting as the placement agents hereunder pursuant the indemnification provisions set forth in the Engagement Letter.
10.15Waiver of Potential Conflicts of Interest. Each of the Purchasers and the Company acknowledges that Wilson Sonsini Goodrich & Rosati, Professional Corporation (“WSGR”) may have represented and may currently represent certain of the Purchasers. In the course of such representation, WSGR may have come into possession of confidential information relating to such Purchasers. Each of the Purchasers and the 
24

Company acknowledges that WSGR is representing only the Company in this transaction. Each of the Purchasers and the Company understands that an affiliate of WSGR may also be a Purchaser under this Agreement. By executing this Agreement, each of the Purchasers and the Company hereby waives any actual or potential conflict of interest which may arise as a result of WSGR’s representation of such persons and entities, WSGR’s possession of such confidential information and the participation by WSGR’s affiliate in the financing. Each of the Purchaser and the Company represents that it has had the opportunity to consult with independent counsel concerning the giving of this waiver.
[Signature page follows]

25

IN WITNESS WHEREOF, the Company has duly executed this Agreement as of March 30, 2022.
MEDAVAIL HOLDINGS, INC.

By:                      
Name:   Ramona Seabaugh
Title:   Chief Financial Officer

26

IN WITNESS WHEREOF, the Purchaser has duly executed this Agreement as of March 30, 2022.
PURCHASER

REDMILE CAPITAL FUND, LP
By: Redmile Group, LLC, its investment manager

By:                     
Name: Joshua Garcia
Title:  Authorized Signatory

Address of Executive Offices:

One Letterman Drive, Suite D3-300    
San Francisco, CA 94129    
    

IRS Tax Identification Number: 

     

Telephone Number: 

415-489-9980    

Facsimile Number:

N/A    

E-mail Address: 

operations@redmilegrp.com    

Additional copies of notices pursuant to the Agreement shall be delivered but not constitute notice, to:

N/A    
Email:    
Facsimile:    ____________________

27

IN WITNESS WHEREOF, the Purchaser has duly executed this Agreement as of March 30, 2022.
PURCHASER

REDMILE CAPITAL OFFSHORE MASTER FUND, LTD.
By: Redmile Group, LLC, its investment manager

By:                     
Name: Joshua Garcia
Title:  Authorized Signatory

Address of Executive Offices:

One Letterman Drive, Suite D3-300    
San Francisco, CA 94129    
    

IRS Tax Identification Number: 

     

Telephone Number: 

415-489-9980    

Facsimile Number:

N/A    

E-mail Address: 

operations@redmilegrp.com    

Additional copies of notices pursuant to the Agreement shall be delivered but not constitute notice, to:

N/A    
Email:    
Facsimile:    ____________________

28

IN WITNESS WHEREOF, the Purchaser has duly executed this Agreement as of March 30, 2022.
PURCHASER

REDMILE STRATEGIC MASTER FUND, LP – CLASS C
By: Redmile Group, LLC, its investment manager

By:                     
Name: Joshua Garcia
Title:  Authorized Signatory

Address of Executive Offices:

One Letterman Drive, Suite D3-300    
San Francisco, CA 94129    
    

IRS Tax Identification Number: 

     

Telephone Number: 

415-489-9980    

Facsimile Number:

N/A    

E-mail Address: 

operations@redmilegrp.com    

Additional copies of notices pursuant to the Agreement shall be delivered but not constitute notice, to:

N/A    
Email:    
Facsimile:    ____________________

29

IN WITNESS WHEREOF, the Purchaser has duly executed this Agreement as of March 30, 2022.
PURCHASER

REDMILE STRATEGIC MASTER FUND, LP – CLASS D
By: Redmile Group, LLC, its investment manager

By:                     
Name: Joshua Garcia
Title:  Authorized Signatory

Address of Executive Offices:

One Letterman Drive, Suite D3-300    
San Francisco, CA 94129    
    

IRS Tax Identification Number: 

     

Telephone Number: 

415-489-9980    

Facsimile Number:

N/A    

E-mail Address: 

operations@redmilegrp.com    

Additional copies of notices pursuant to the Agreement shall be delivered but not constitute notice, to:

N/A    
Email:    
Facsimile:    ____________________
30

IN WITNESS WHEREOF, the Purchaser has duly executed this Agreement as of March 30, 2022.
PURCHASER
REDCO II MASTER FUND, L.P.
By: RedCo II (GP), LLC, its general partner
By:                     
Name: Joshua Garcia
Title:  Authorized Signatory
Address of Executive Offices:
One Letterman Drive, Suite D3-300    
San Francisco, CA 94129    
    
IRS Tax Identification Number: 
     
Telephone Number: 
415-489-9980    
Facsimile Number:
N/A    
E-mail Address: 
operations@redmilegrp.com    
Additional copies of notices pursuant to the Agreement shall be delivered but not constitute notice, to:
N/A    
Email:    
Facsimile:    ____________________

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the Company has duly executed this Agreement as of March 30, 2022.
PURCHASER
ALLY BRIDGE MEDALPHA MASTER FUND L.P.
By: Ally Bridge Group (NY) LLC, its manager
By:                     
Name: Anna Yaeger
Title:  President and Portfolio Manager
Address of Executive Offices:
430 Park Avenue, 12th Floor    
New York, NY 10022    
    
IRS Tax Identification Number: 
     
Telephone Number: 
(646) 809-3771    
Facsimile Number:
N/A    
E-mail Address: 
michael.bendetson@ally-bridge.com    

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the Company has duly executed this Agreement as of March 30, 2022.
PURCHASER
ABG WTT-MEDAVAIL LIMITED
By:                     
Name: Chon Charles Chungsik, its Director
Address:
Unit 3002-3004, 30/F.,
Gloucester Tower The Landmark,
15 Queen’s Road Central, Hong Kong

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the Company has duly executed this Agreement as of March 30, 2022.
PURCHASER
ALYESKA INVESTMENT GROUP, L.P.
By:                     
Name: 
Title:  
Address of Executive Offices:
    
    
    
IRS Tax Identification Number: 
    
Telephone Number: 
    
Facsimile Number:
    
E-mail Address: 
    
Additional copies of notices pursuant to the Agreement shall be delivered but not constitute notice, to:
    
    
    
    
Email:    
Facsimile:    
IN WITNESS WHEREOF, the Company has duly executed this Agreement as of March 30, 2022.
[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

PURCHASER
FCP Biotech Holding GmbH
By: Stefan Heisserer
Name: Managing Director
Title: FCP Biotech Holding GmbH  
Address of Executive Offices:

FCP Biotech Holding GmbH
Freihamer Str. 2
82166 Graefelfing
Germany
IRS Tax Identification Number: 
    
Telephone Number: 
    
Facsimile Number:
    
E-mail Address: 
    
Additional copies of notices pursuant to the Agreement shall be delivered but not constitute notice, to:
    
    
    
    
Email:    
Facsimile:    
[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

Schedule I

Schedule of Purchasers
First Closing: 
												
	Name	Shares of Common Stock	Purchase Price	Warrant Shares
	Redmile Capital Fund, LP	1,417,282	$1,505,862.13	708,641
	Redmile Capital Offshore Master Fund, Ltd.	399,207	$424,157.44	199,603
	Redmile Strategic Master Fund, LP – Class C	475,165	$504,862.81	237,582
	Redmile Strategic Master Fund, LP – Class D	367,313	$390,270.06	183,656
	RedCo II Master Fund, L.P.	11,458,679	$12,174,846.44	5,729,339
	ABG WTT-MEDAVAIL LIMITED	11,143,529	$11,839,999.57	5,571,764
	ALLY BRIDGE MEDALPHA MASTER FUND L.P.	2,974,117	$3,159,999.32	1,487,058
	ALYESKA MASTER FUND, L.P.	7,529,411	$7,999,999.19	3,764,705
	FCP Biotech Holding GmbH	1,882,352	$1,999,999.00	941,176
	Total	#VALUE!	#VALUE!	#VALUE!

Second Closing:
[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

												
	Name	Shares of Common Stock	Purchase Price	Warrant Shares
	Redmile Capital Fund, LP	944,855	$1,003,908.44	472,427
	Redmile Capital Offshore Master Fund, Ltd.	266,139	$282,772.69	133,069
	Redmile Strategic Master Fund, LP – Class C	316,778	$336,576.63	158,389
	Redmile Strategic Master Fund, LP – Class D	244,876	$260,180.75	122,438
	RedCo II Master Fund, L.P.	7,639,117	$8,116,561.81	3,819,558
	Total	#VALUE!	#VALUE!	#VALUE!

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

Schedule II
Disclosure Schedule
Section 4.04 (Capitalization)
    The Company has proposed adopting an equity inducement plan of 1,500,000 shares of Common Stock.

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

Exhibit A

Form of Warrant

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

Exhibit B

Form of Legal Opinion of Wilson Sonsini Goodrich & Rosati, 
Professional Corporation

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

Exhibit C

Registration Rights Agreement

[SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]